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ABSTRACT 
 
MODELING SPORADIC TUMOR FORMATION DRIVEN BY TELOMERE 
DYSFUNCTION IN THE GASTROINTESTINAL TRACT 
Publication No.__________ 
 
Suzanne S. Chan 
Supervisory Professor: Sandy Chang, M.D., Ph.D. 
 
Colorectal cancer is a complex disease that is thought to arise when cells accumulate 
mutations that allow for uncontrolled growth. There are several recognized mechanisms for 
generating such mutations in sporadic colon cancer; one of which is chromosomal instability 
(CIN). One hypothesized driver of CIN in cancer is the improper repair of dysfunctional 
telomeres. Telomeres comprise the linear ends of chromosomes and play a dual role in 
cancer. Its length is maintained by the ribonucleoprotein, telomerase, which is not a normally 
expressed in somatic cells and as cells divide, telomeres continuously shorten. Critically 
shortened telomeres are considered dysfunctional as they are recognized as sites of DNA 
damage and cells respond by entering into replicative senescence or apoptosis, a process that 
is p53-dependent and the mechanism for telomere-induced tumor suppression. Loss of this 
checkpoint and improper repair of dysfunctional telomeres can initiate a cycle of fusion, 
bridge and breakage that can lead to chromosomal changes and genomic instability, a process 
that can lead to transformation of normal cells to cancer cells. Mouse models of telomere 
dysfunction are currently based on knocking out the telomerase protein or RNA component; 
however, the naturally long telomeres of mice require multiple generational crosses of 
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telomerase null mice to achieve critically short telomeres.  Shelterin is a complex of six core 
proteins that bind to telomeres specifically. Pot1a is a highly conserved member of this 
complex that specifically binds to the telomeric single-stranded 3’ G-rich overhang. Previous 
work in our lab has shown that Pot1a is essential for chromosomal end protection as deletion 
of Pot1a in murine embryonic fibroblasts (MEFs) leads to open telomere ends that initiate a 
DNA damage response mediated by ATR, resulting in p53-dependent cellular senescence. 
Loss of Pot1a in the background of p53 deficiency results in increased aberrant homologous 
recombination at telomeres and elevated genomic instability, which allows Pot1a-/-, p53-/- 
MEFs to form tumors when injected into SCID mice. These phenotypes are similar to those 
seen in cells with critically shortened telomeres.  
 In this work, we created a mouse model of telomere dysfunction in the 
gastrointestinal tract through the conditional deletion of Pot1a that recapitulates the 
microscopic features seen in severe telomere attrition. Combined intestinal loss of Pot1a and 
p53 lead to formation of invasive adenocarcinomas in the small and large intestines. The 
tumors formed with long latency, low multiplicity and had complex genomes due to 
chromosomal instability, features similar to those seen in sporadic human colorectal cancers. 
Taken together, we have developed a novel mouse model of intestinal tumorigenesis based 
on genomic instability driven by telomere dysfunction. 
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INTRODUCTION 
Colon cancer and chromosomal instability 
Colon cancer is the third most common cause of cancer, as well as the third leading 
cause of cancer death in both men and women in the United States(ACS, 2010).  Cancer is a 
complex disease that arises when cells accumulate mutations that allow for uncontrolled 
growth. The progression of colorectal tumorigenesis has been characterized as a step-wise 
progression from adenoma to carcinoma to metastasic disease(Fearon and Vogelstein, 1990) 
as these mutations accumulate (Figure 1). Some of the important genes involved in some of 
the transitions are well known, such as activation of the Wnt signaling pathway especially 
through loss of APC(Goss and Groden, 2000). However, recent work with cancer genomics 
have revealed that colorectal cancer cells harbor very complex genomes with a multitude of 
genetic changes, so there are may be many other genes important for cancer progression, 
especially the metastatic transition, that have yet to be elucidated. 
There are several mechanisms that drive the accumulation of genetic alterations, 
which can fuel colon cancer formation and progression. Genetic alterations can include 
subtle sequence changes, alterations in chromosome numbers, chromosome translocations 
and gene amplifications(Lengauer et al., 1997). These types of changes can be a consequence 
of chromosomal instability or defects in the DNA repair pathways(Markowitz and 
Bertagnolli, 2009). The mismatch repair (MMR) pathway is one such DNA repair 
mechanism that is found in colon cancers. Inactivation of MMR genes, such as MLH1 or 
MSH2, leads to a phenotype called microsatellite instability (MSI), which targets simple 
repeat sequences in the genome(Rajagopalan et al., 2003). MSI is most associated with 
patients with hereditary  
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Figure 1: The Vogelstein model of colon cancer progression. Colorectal cancers 
develop first as small benign adenomas and follow a progression to malignant 
adenocarcinomas and finally to metastasis. Some of the genetic alterations associated 
with various steps of the pathway have been elucidated and are outlined above (dotted 
boxes).   
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non-polyposis colorectal cancer (HNPCC), but can also be seen in 15% of sporadic 
tumors(Markowitz and Bertagnolli, 2009; Rajagopalan et al., 2003).   
On the other hand, chromosomal instability (CIN) is seen in 85% of sporadic colon 
cancers and is thought to be a major driver of genomic instability(Rajagopalan et al., 2003). 
CIN can cause cells to gain or lose large pieces or entire chromosomes leading to aneuploidy 
and gene copy number variations (CNV)(Lengauer et al., 1997; Rajagopalan et al., 2003). 
Here, we will explore one mechanism that may be involved in driving CIN during 
tumorigenesis: dysfunctional telomeres.  
 
The telomere-cancer paradox 
Telomeres are located at the terminal ends of chromosomes. They consist of tandem 
TTAGGG repeats and end with a 3’ single stranded G-rich overhang (Figure 2). This 
overhang is thought to invade the upstream duplex telomere DNA to effectively hide the end 
and create a structure called a t-loop(Griffith et al., 1999). It is bound by a complex of 
telomere specific proteins called shelterin(de Lange, 2005). The main function of telomeres 
is to protect the chromosomal ends from being recognized as sites of DNA damage or being 
exposed to nuclease degradation with subsequent loss of genetic information(Verdun and 
Karlseder, 2007). The length of telomeres can be maintained by a ribonucleoprotein called 
telomerase, which consists of two main components:  a reverse transcriptase protein (TERT) 
and a RNA component (TERC) that serves as a template for elongation.  
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Figure 2: The structure of telomeres. Telomeres are located at the terminal ends of 
chromosomes. They consist of tandem TTAGGG repeats and end with a 3’ single 
stranded G-rich overhang. This overhang is thought to invade the upstream duplex 
telomere DNA that effectively hides the end and creating a structure called a t-loop.  
TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG 
-3’ AATCCC AATCCCAATCCCAATCCCAATCCCAATCCCAATCCC -5’ 
3’ G-rich overhang 
(50-500nt) 
t-loop 
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In humans, telomerase activity is in limited to germ cells and stem cells, but absent in 
most somatic cells. Without telomerase maintenance, the overall length of telomeres shortens 
with each cell division due the inability of DNA replication machinery to fully replicate the 
lagging strand DNA, a characteristic termed the end replication problem. It is estimated that 
humans lose between 2-4 kb of telomeric DNA in a lifetime. Considering human telomere 
lengths average 8-12kb, this amount of loss may be significant and might play a role in 
organismal aging(Blasco, 2007).  Increasing age is the biggest risk factor for sporadic colon 
cancer formation, so it stands to reason that telomeres may provide the link between aging 
and cancer(DePinho, 2000). Accordingly, telomere length has been shown to correlate with 
age in normal intestinal mucosa(Rampazzo et al.). Furthermore, telomeres in colorectal 
tumor tissue are shorter than the surrounding normal mucosa(Rampazzo et al.). Therefore it 
is postulated that telomere erosion may be a key initiating event in the colon tumor 
formation. 
Telomeres plays a dual role in cancer (Artandi and DePinho; Deng et al., 2008). First, 
there is a limit to the amount of telomere attrition that a cell can tolerate. This phenomenon 
was originally described by Hayflick and Moorhead, who observed that primary human 
diploid fibroblasts cannot be cultured indefinitely(Hayflick and Moorhead, 1961). There is a 
limit to the number of population doublings that a culture can be passaged, after which the 
cells enter into a state of permanent cell cycle arrest termed replicative senescence. This 
checkpoint is the basis of the first half of the telomere-cancer paradox: telomere-dependent 
tumor suppression(Deng et al., 2008). 
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 Replicative senescence is thought to be a consequence of the DNA damage response 
to telomere attrition. Senescent fibroblasts stained positively for markers of DNA damage, 
such as phosphorylated histone H2AX (γ-H2AX) and p53 binding protein 1 (53BP1)(d'Adda 
di Fagagna et al., 2003). Critically short telomeres also activate sensors of DNA damage such 
as the phosphatidylinositol 3-kinase (PIKKs): ataxia telangiectasia mutated (ATM) and 
ataxia telangiectasia- and Rad3- related protein (ATR)(d'Adda di Fagagna et al., 2003). 
These proteins in turn activate the downstream transducers, CHK1 and CHK2, which go on 
to activate p53(Gire et al., 2004),  the protein that ultimately triggers cell cycle 
arrest/senescence through p21. While the Ink4a/Rb pathway may also play a role in this 
process that is less understood (Jacobs and de Lange, 2004; Kim and Sharpless, 2006), it is 
the p53-dependent senescence or apoptosis that is thought to mediate the first checkpoint in 
telomere-induced tumor suppression.  
Inactivation of p53 or Rb can bypass this checkpoint and allow fibroblasts to continue 
to proliferate (Hara et al., 1991; Shay et al., 1991). Telomere attrition continues and the 
resulting dysfunctional telomeres lead to genomic instability. When the deprotected ends are 
recognized as double strand breaks, DNA repair mechanisms, such as non-homologous end 
joining (NHEJ) or homologous recombination (HR), are activated to produce fusions with 
other chromosomes resulting in a dicentric chromosome. When the dicentric chromosome is 
pulled to opposite poles during anaphase, a bridge is formed between the two cells, called an 
anaphase bridge. In order for cytokinesis to occur, the anaphase bridge must break to 
separate. This break is random and creates amplification in one cell and a corresponding 
deletion in the other cell. The new breaks must then be repaired through the same pathways, 
resulting in new fusions that will form another bridge and the process repeats. This cycle is 
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called the break-fusion-bridge (BFB) cycle and was first noticed by Barbara McClintock 
during her studies of maize(McClintock, 1941). Since the sites of breakage and repair are 
random, one can see how repeated cycles of BFB triggered by just a few fusions can lead to 
changes in the integrity of the genome, either through large losses or amplifications of 
genetic information. This rampant genomic instability can lead to the accumulation of 
oncogenic changes necessary for a cell to become transformed. Therefore, activation of the 
BFB cycle through dysfunctional telomeres represent the second half of the telomere-cancer 
paradox: dysfunctional telomere-induced genomic instability can promote tumor formation 
(Bailey and Murnane, 2006; DePinho and Polyak, 2004).  
While there are many studies associating telomere length to human disease(Jiang et 
al., 2007), much of our direct knowledge of in vivo consequences of telomere dysfunction 
has come from the telomerase knockout mouse. In this model, gene targeting of the RNA 
component of telomerase (mTerc) efficiently disrupts the function of telomerase. However, 
owing to the differences in the length of laboratory mouse telomeres (40-80kb) compared to 
human telomeres (8-12kb), it takes successive intergenerational breeding of mTerc-/- animals 
to reach critical shortening. It is only at later generations (G4 or beyond) that one begins to 
see the effects of shortened telomeres(Lee et al., 1998; Rudolph et al., 1999). We sought to 
avoid this process by approaching telomere dysfunction from a different angle: targeting the 
telomere binding complex, shelterin. 
 
The shelterin complex 
 The term “dysfunctional telomeres” refers to a state of deprotected telomeres that can 
be caused by severe shortening or by uncapping due to disruption of the shelterin 
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components(Harrington and Robinson, 2002). Shelterin is composed of six proteins that bind 
specifically to telomeres, including: TRF1, TRF2, TIN2, RAP1, TPP1 and POT1(de Lange, 
2005) (Figure 3). They are all essential to cell survival, as depletion of shelterin components 
either drives cells into cellular senescence or results in early embryonic lethality. Together, 
these six proteins form a complex that maintains telomeric length and structure, and protects 
chromosome ends from activating the DNA damage response and inappropriate repair 
mechanisms. However, each protein plays a unique role in telomere homeostasis. 
The two main proteins that anchor the complex to the double stranded telomeric DNA 
are telomeric repeat-binding factors 1 and 2 (TRF1 and TRF2), which recognize duplex 
TTAGGG repeats and bind directly through their SANT/Myb domain(Broccoli et al., 1997). 
Although TRF1 and TRF2 have similar structure and protein binding domains, they recruit 
proteins to telomeres differently (Chen et al., 2008) and play distinct roles in protection of 
chromosome ends. TRF2 appears to be a vital component of shelterin as its loss is very toxic 
to cells. Depletion of TRF2 from cells initiates a potent DNA damage response, which leads 
to cellular senescence or very dramatic fusion phenotype indicative of improper activation of 
NHEJ (Karlseder et al., 1999; van Steensel et al., 1998). This response suggests that it plays a 
prominent role in suppressing both these processes at normal chromosome ends. While the 
exact method of repression of these pathways is still speculative, TRF2 has been shown to 
interact with other proteins, including the shelterin protein RAP1 (Li et al., 2000), as well as 
a variety of non-shelterin proteins, including ATM, the MRN complex, WRN, BLM, Ku86, 
ERCC1/XPF, PARP1 and PARP2 (Palm and de Lange, 2008). Many of these proteins are 
involved DNA damage sensing and repair processes, leading to the theory that TRF2 
repression of these pathways is mediated by physical interactions with these factors. TRF2 
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may also play a role in stabilizing telomere secondary structure as it has been shown to 
facilitate t-loop formation in vitro (Stansel et al., 2001). 
Although it can also bind double stranded telomeric DNA, TRF1 appears to play a 
minor role in repression of damage responses and repair. Its depletion also leads to cellular 
senescence(Karlseder et al., 2003; Martinez et al., 2009; Sfeir et al., 2009), but in vitro 
experiments show that TRF1 is unable to inhibit end-joining of telomeric substrates(Bae and 
Baumann, 2007).  Instead, TRF1 may be more important in regulation of telomere 
length(Smogorzewska et al., 2000; van Steensel and de Lange, 1997). It can interact with 
non-shelterin telomere factors, including PINX1, Tankyrase 1 and Tankyrase 2(Palm and de 
Lange, 2008). These factors can in turn interact with telomerase, suggesting telomere length 
regulation involves TRF1 recruitment of these factors to telomeres. There is emerging 
evidence that TRF1 may also be important for preventing telomere replication mistakes and 
protects telomeres against a fragile-telomere phenotype (Martinez et al., 2009; Sfeir et al., 
2009).  
The TRF1-interacting nuclear protein 2 (TIN2) has been called the linchpin of 
shelterin, as it is able to bind TRF1, TRF2 and TPP1, acting as a bridge between the double 
stranded and single stranded telomere binding proteins. While it can stabilize the six protein 
complex(O'Connor et al., 2006), TIN2 exists in stoichiometric quantities enough to bind each 
molecule of TRF1 or TRF2, suggesting that it may not always bind to both proteins 
simultaneously and that the shelterin complex may not always exist with all 
components(Takai et al.).  It was recently discovered that TIN2 exists in two isoforms in 
human cells. One of these isoforms, TIN2L, was shown to bind tightly to nuclear matrix 
proteins suggesting a role in anchoring telomeres in the nucleus(Kaminker et al., 2009).   
  - 10 - 
 
Figure 3: The shelterin complex. Telomeres are bound by a complex of telomere 
specific proteins called shelterin, which includes TRF1, TRF2, TIN2, TPP1, POT1 
and RAP1. TRF1 and TRF2 bind directly to duplex telomeric DNA, while POT1 
binds to the single stranded G-rich 3’ overhang. TIN2 bridges TRF1 and TRF2, while 
connecting POT1 to these molecules through TPP1. RAP2 localizes to telomeres 
through its interaction with TRF2.  
AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG -3’ 
TCCC AATCCC AATCCCAATCCC AATCCCAATCCCAATCCC AATCCC -5’ 
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TPP1 can interact with TIN2 and POT1, providing the essential link for the 
recruitment of POT1 to telomeres(Hockemeyer et al., 2007). As with other members of 
shelterin, homozygous loss of TPP1 is incompatible with survival(Kibe et al.). Depletion of 
TPP1 through genetic ablation(Kibe et al.), RNA interference(Guo et al., 2007), or a mutant 
that abolishes POT1 interaction(Guo et al., 2007) leads to cellular consequences consistent 
with POT1 loss, suggesting its main role is the recruitment of POT1 to the chromosome ends. 
TPP1 can also interact with telomerase, suggesting that it may play role in telomere length 
maintenance(Xin et al., 2007).  
Originally discovered in S. pombe, protection of telomeres (POT1) is the component 
that specifically binds to the single stranded G-rich overhang. It was found based on its 
similarity to the ciliate telomere binding protein TEBPα(Baumann and Cech, 2001). It is 
essential for the protection of telomeres in yeast as its loss leads to cell death, where the only 
surviving colonies have circularized their chromosomes eliminating the need for telomere 
protection(Baumann and Cech, 2001). It is one of the most highly conserved members of 
shelterin and has been studied in humans, chicken, mice, yeast and plants(Churikov and 
Price, 2008; He et al., 2006; Hockemeyer et al., 2006; Hockemeyer et al., 2007; Loayza and 
De Lange, 2003; Wang et al., 2007). All POT1 proteins have two highly conserved 
oligonucleotide/oligosaccharide binding folds (OB folds) that show specificity for telomeric 
sequences and are essential for binding the single stranded 3’ overhang. Human POT1 
associates with the rest of the shelterin complex through its interaction with TPP1, an 
interaction that appears essential for its function(Hockemeyer et al., 2007). It is also a vital 
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component in telomere protection as knockdown of POT1 also triggers a chromosomal 
aberrations and cell death(Wu et al., 2006).  
Mice have two orthologs of the gene, named Pot1a and Pot1b(Hockemeyer et al., 
2006; Wu et al., 2006). Pot1a is essential to cells as targeted deletion of this gene in the 
mouse leads to embryonic lethality very early during development (Hockemeyer et al., 2006; 
Wu et al., 2006). Pot1a is necessary for chromosomal end protection as deletion of Pot1a in 
murine embryonic fibroblasts (MEFs) promotes chromosomal fusions and a DNA damage 
response resulting in cellular senescence(Wu et al., 2006). On the other hand, Pot1b is not 
essential for survival as Pot1b-/- mice are viable, and its deficiency in cells does not produce 
as severe of a phenotype as loss of Pot1a alone or deletion of both Pot1a and Pot1b(He et al., 
2006; Hockemeyer et al., 2006). Recent studies have implicated Pot1b in telomeric length 
maintenance; in particular, the regulation of C-strand resection for the formation of the 3’ 
overhang, which is greatly elongated following Pot1b loss(He et al., 2006; Hockemeyer et 
al., 2006; Hockemeyer et al., 2008).  
RAP1 is one of the most evolutionarily conserved members of shelterin. However, its 
role in telomere biology seems to vary between species. For instance, in S. cerevisiae, rap1 
binds directly to telomeric sequences, where it is involved in the negative regulation of 
telomere length, inhibition of fusions, and the recruitment of Sir proteins for silencing of 
genes near the telomeric region (Hardy et al., 1992). However, in mammalian cells, RAP1 
cannot bind telomeric DNA and depends on TRF2 binding for recruitment to chromosome 
ends(Li et al., 2000). Biochemical assays have revealed that the TRF2/RAP1 complex can 
inhibit NHEJ-mediated fusions at telomeric ends(Bae and Baumann, 2007), but because of 
this dependence, the role of RAP1 alone remains unclear. In vitro studies in human cell lines 
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suggest overexpression of RAP1 may have an effect on telomere length regulation, which is 
independent of its ability to localize to telomeres(Li and de Lange, 2003). Recent generation 
of  a fusion protein between RAP1 and the telomeric binding domain of a yeast protein 
allowed localization of RAP1 to telomeres independent of TRF2 binding(Sarthy et al., 2009). 
Using this fusion protein, localization of RAP1 to telomeres did not prevent DNA damage 
signaling, but was sufficient to inhibit NHEJ(Sarthy et al., 2009) suggesting that RAP1 plays 
more of a role in repression of repair rather that damage sensing. 
 
How shelterin protects telomeres 
The linear nature of eukaryotic chromosomes presents a difficult problem for cells: 
how can cellular DNA damage response machinery distinguish the normal ends of 
chromosomes from sites of DNA breaks? Or alternatively, how can chromosomes mask its 
ends from activating this response so that cells can propagate? This obstacle has been 
deemed the “end protection problem”(de Lange, 2009). Telomeres function to solve this 
problem, and as discussed above, severe erosion of telomeres exposes chromosome ends to a 
potent DNA damage response(d'Adda di Fagagna et al., 2003; Gire et al., 2004), resulting in 
p53-dependent senescence or apoptosis (Figure 4).   
The role shelterin proteins play in suppressing this response at normal telomeres has 
been teased out through the use of mouse embryonic fibroblasts (MEFs) with genetic 
ablation of various combinations of these factors. First, TRF2 knockdown experiments show 
that cells respond to loss of TRF2 in a similar manner as IR-induced DSB, with the MRN 
complex required for the initial sensing of damage at dysfunctional telomeres(Deng et al., 
2009; Dimitrova and de Lange, 2009), while ATM is necessary for propagation of the 
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signal(Denchi and de Lange, 2007; Guo et al., 2007). On the other hand, TPP1 or Pot1a/b 
disruption leads to a response that is dependent on the ATR pathway (Denchi and de Lange, 
2007; Guo et al., 2007). These results reveal that TRF2 acts mainly to repress ATM-mediated 
DNA damage responses, while Pot1a and Pot1b are involved in repression of the ATR 
pathway (Figure 4). How TRF2 and POT1 act to inhibit these pathways is still unclear. 
Paradoxically, many components of DDR  pathways can be found normally at telomeres 
without activating an apparent DNA damage response(Verdun et al., 2005). Given that TRF2 
can interact with these non-shelterin telomeric factors, perhaps it directly suppresses their 
activation through physical inhibition. In fact, there is some evidence that the TRF2 
interaction with ATM directly inhibit its activity(Karlseder et al., 2004). However, POT1 
proteins are not known to interact with non-shelterin components. Instead, it is postulated 
that the binding of the POT1 proteins to the 3’ overhang provides protection through 
competitive blockade of RPA binding to the single stranded protrusion, preventing the 
activation of the ATR pathway (Zou and Elledge, 2003).  
 
Targeted deletion of Pot1a to model telomere dysfunction in vivo 
Given the similarities the consequences of disruption of shelterin components have to 
severe telomere attrition (Figure 4), we decided to target Pot1a in this project to study 
telomere dysfunction in vivo.  With the parallels seen between the responses of both types of 
dysfunctional telomeres, we believe that the in vivo consequences of loss of Pot1a will also 
mimic that of mice with critically short telomeres. We used the conditional Pot1a knockout 
mouse(Wu et al., 2006) to allow us to take advantage of the different models of tissue-
specific expression of the Cre recombinase to focus on the affect of telomere dysfunction on 
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Figure 4. Consequences of telomere dysfunction. Work in human and mouse 
cells, as well as the telomerase null mouse models, have shown that telomere 
dysfunction caused by severe telomere shortening activates a DNA damage 
response (DDR) mainly mediated by the ATM/ATR pathway, which ultimately 
leads to p53-dependent apoptosis or senescence. Recent studies in mouse cells 
have shown that telomere dysfunction due to uncapping through loss of the 
shelterin proteins activate a similar response resulting in p53 activation and 
cellular senescence or apoptosis. TRF2 mainly suppresses an ATM-dependent 
response, while POT1 protects against ATR-dependent DDR.  
Telomere shortening 
Telomere uncapping 
? 
INK4A 
CDK4, 
CDK6 
RB 
Senescence Apoptosis 
TRF2 loss 
ATM 
CHK2 
p53 
Senescence Apoptosis 
ATM, 
ATR 
CHK1, 
CHK2 
p53 
p21 p21  
POT1 loss 
ATR 
CHK1 
p53 
p21  
  - 16 - 
 
one organ system at a time. This reduces the possibility of confounding factors that may arise 
with telomere dysfunction throughout the organism, such as the hematopoietic compromise 
that affects late generation telomerase null mice(Lee et al., 1998; Rudolph et al., 1999).  In 
this project, we focused on the gastrointestinal system, which, as one of the body’s most 
proliferative compartments, telomere dysfunction is postulated to play a role due to the 
multiple rounds of cell division necessary to maintain the level of tissue renewal.  
Similar to results seen in cell culture experiments, our mice show that intestinal 
deletion of Pot1a leads to a DNA damage response in cells of the crypts of Lieberkuhn, 
which activates p53 leading to upregulation of p21 and increased apoptosis. These 
phenotypes are also seen in the gut of late generation telomerase null mice with severe 
telomere shortening(Rudolph et al., 1999). Loss of Pot1a in the background of p53 deficiency 
results in increased aberrant homologous recombination at telomeres and elevated genomic 
instability, which allows Pot1a-/-, p53-/- MEFs to form tumors when injected into SCID 
mice(Wu et al., 2006). Similarly, mice with combined Pot1a and p53 formed tumors in the 
small intestines and colon. The mouse model produced invasive adenocarcinomas with low 
multiplicity, long latency, but high penetrance. Analysis of these tumors showed complex 
genomes with heterogeneity in genetic alterations between tumors, indicative of genomic 
instability. Taken together, the data we present here demonstrate that intestinal deletion of 
Pot1a and p53 produced a mouse model sporadic gastrointestinal cancer driven by telomere-
induced genomic instability.   
 
  - 17 - 
 
RESULTS 
 
GENERATION OF A MOUSE MODEL OF TELOMERE-DYSFUNCTION IN THE 
GASTROINTESTINAL TRACT THROUGH LOSS OF POT1A 
Generation and validation of the Villin-Cre Pot1a mouse colony 
Since homozygous loss of Pot1a leads to embryonic lethality, we used a conditional 
knockout mouse previously created in our lab, in which exons 4 and 5 of the Pot1a gene are 
flanked by loxP sites(Wu et al., 2006). Exon 4 contains the translational start site and exon 5 
contains part of the first OB-fold. The gastrointestinal tract was targeted by crossing the 
conditional Pot1a mouse with a Villin-Cre (VCre) transgenic mouse, which specifically 
expresses the Cre recombinase in intestinal epithelia through the Villin promoter(Madison et 
al., 2002). These mice were mated to produce the three cohorts used for this study (Table 1): 
one group which does not possess the VCre transgene and should therefore have wild-type 
Pot1a in the intestines (VCre-); one consisting of VCre+ Pot1a+/+ or Pot1aF/+mice, which 
express the Cre recombinase, but retain one or both wild-type alleles of Pot1a in the 
intestines (VCre+); and the mutant cohort of VCre+ Pot1aF/F mice with both copies of Pot1a 
deleted in the intestines (Pot1aint∆). A mating set-up between VCre- Pot1aF/+ and VCre+ 
Pot1aF/+ revealed that Pot1aint∆ are viable and born at expected Mendelian ratio (Table 1).  
Cre-mediated deletion of the Pot1a allele was determined indirectly through several different 
methods. First, we developed a PCR strategy that is able to detect the recombination event in 
which exons 4 and 5 are deleted. This method can distinguish between this “delta” allele and 
the intact “floxed” conditional allele (Figure 5A). Genomic DNA was isolated from various 
tissue samples harvested from Pot1aint∆ mice and assayed for the presence of the delta band.  
  - 18 - 
 
Table 1: Cohorts for study in the Villin-Cre, Pot1a colony and progeny distribution. 
The table below lists the three main cohorts studied and the genotypes included in those 
cohorts. Results from a VCre- Pot1aF/+ x VCre+ Pot1aF/+ cross show that mice with 
homozygous deletion of Pot1a in the intestines (VCre+ Pot1aF/F) are viable and observed in 
approximately the expected Mendelian ratios. 
 
Cohort name Genotypes included Expected Observed 
VCre- 
VCre- Pot1a+/+ 
VCre- Pot1aF/+ 
VCre- Pot1aF/F 
1/8 (12.5%) 
1/4 (25%) 
1/8 (12.5%) 
14 (13.2%) 
25 (23.5%) 
13 (12.3%) 
VCre+  
*VCre+ Pot1a+/+ 
*VCre+ Pot1aF/+ 
1/8 (12.5%) 
1/4 (25%) 
12 (11.3%) 
27 (25.4%) 
Pot1aint∆ VCre+ Pot1aF/F 1/8 (12.5%) 15 (14.1%) 
  Total: 106 mice 
* These two cohorts of mice behave very similarly since heterozygous loss of Pot1a has no 
apparent affect on cells in vitro or in vivo. 
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Figure 5: Pot1a deletion is restricted to the intestines. Panel A shows the PCR 
strategy for detecting Pot1a deletion from genomic PCR. Primers 1 & 3 are used to 
detect the null allele. Primers 2 & 3 are used to distinguish the floxed allele vs. the WT 
allele, and serve as an internal control for the PCR reaction. DNA was extracted from 
several different organs from a Pot1aint∆ mouse. PCR analysis shows that the ∆Pot1a 
band is only amplified in genomic DNA harvested from the small intestine, cecum and 
colon; and not in other organs, including the stomach (Panel B).  
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The Villin-Cre transgene is only active in the intestinal epithelial cells and not in other 
tissues, including the liver and stomach(Madison et al., 2002). Accordingly, PCR results 
showed that the delta band was only amplified in samples harvested from the small intestine, 
cecum and colon, but not the stomach, kidney, liver, heart or spleen (Figure 5B). These 
results confirm that deletion of Pot1a occurs preferentially in the gastrointestinal tract.  
To measure the expression of Pot1a mRNA, RT-PCR was performed using a Taqman 
Gene Expression Assay with probes specific for a region located in exon 4 of the Pot1a gene. 
RNA was isolated from liver tissue and scrapings of epithelial cells from the small intestine 
and colon. Analysis of tissues from VCre+ Pot1aF/+ mice demonstrated that loss of one allele 
of Pot1a leads to approximately 30% reduction in Pot1a expression in both the small intestine 
(0.720±0.046, t-test, p = 0.022) and colon (0.69±0.096, t-test, p = 0.012) (Figure 6). 
Intestines with both alleles of Pot1a deleted (Pot1aint∆ ) showed only a tenth of the expression 
seen in VCre- control small intestines (0.120±0.072, t-test, p<0.001) and colon (0.183±0.104, 
t-test, p<0.001) (Figure 6). These results confirm that conditional deletion of both Pot1a 
alleles leads to a dramatic reduction in Pot1a mRNA expression that is restricted to the small 
intestines and colon.  
Finally, to determine the distribution of the Cre-mediated deletion, we crossed VCre, 
Pot1a mice with the Rosa26-LacZ reporter (R26R) strain(Soriano, 1999) to generate mice of 
all the genotypes of the above cohorts with an additional R26R gene. The R26R transgene 
consists of a loxP-flanked neomycin cassette in front of a lacZ reporter gene driven by the 
Rosa26 promoter, which under normal conditions is not expressed(Soriano, 1999). In the 
presence of Cre recombinase, the neomycin cassette is removed, allowing for expression of 
the reporter transgene. Tissue from the various cohorts produced in this mating were 
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Figure 6: Villin-Cre expression leads to decreased expression of Pot1a mRNA in 
the intestines. RNA was extracted from liver tissue and intestinal scrapings from 
animals in the three cohorts. mRNA expression was analyzed through RT-PCR using 
Taqman probes specific for a region in exon 4 of the Pot1a gene. The above results 
show that animals with no VCre transgene (VCre-) did not show any changes in Pot1a 
expression. The VCre transgene in a Pot1aF/+ animal leads to a slight decrease in Pot1a 
expression in both the small intestine and the colon, but not in the liver. The 
expression of Pot1a is drastically decreased when both copies of Pot1a are deleted 
(Pot1aint∆). (*: p-value = 0.022; **: p-value = 0.012; ***: p-value <0.001) Tissue 
samples from three animals for each genotype were analyzed. RT-PCR reactions were 
performed in triplicate and normalized to GAPDH expression.  
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harvested and assayed for X-gal staining, which is an indicator of the lacZ gene expression 
leading to β-galactosidase (β-gal) activity. X-gal staining was only observed in mice that 
contained both the reporter transgene (R26R+) and the Villin-Cre transgene (VCre+) (Figure 
7). Furthermore, in VCre+ R26R+ animals, blue staining was only seen the small intestines 
and colon, while other tissues, such as the kidney, heart, liver and stomach remained 
unstained (Figure 8).  
Closer inspection revealed that β−gal activity was restricted to the epithelial cells of 
the GI tract, leaving the supporting stroma and muscularis mucosa unstained (Figure 8). 
Interestingly, Pot1aint∆ intestines showed a decrease in staining intensity in both the small 
intestines and colon when compared to VCre+ controls, with some crypts completely devoid 
of X-gal staining (Figure 8, arrows). This suggests that VCre activity and as a result Pot1a 
deletion may not be complete in Pot1aint∆ intestines.  
 
 Pot1aint∆ mice have normal intestinal morphology, but increased apoptosis and 
anaphase bridges 
Mice in the VCre, Pot1a colony were followed for up to 2 years. The majority of 
these mice lived up to two years without overt signs of illness suggesting that loss of Pot1a in 
the intestinal epithelium does not affect overall survival. Accordingly, Kaplan-Meier analysis 
of survival showed that lifespan was not significantly affected by Pot1a deletion (Figure 9). 
Late generation telomerase null mice with critically shortened telomeres show degenerative 
phenotypes in the intestines, such as villous blunting and crypt atrophy, which lead to weight 
loss (Begus-Nahrmann et al., 2009; Rudolph et al., 1999). To determine if loss of Pot1a also 
results in these features, intestines were harvested from three month old animals and  
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Figure 7: β-galactosidase activity is only detected in the intestines when both the 
Rosa26-LacZ (R26R) and the Villin-Cre (VCre) transgenes are present. To 
determine the distribution of Villin-Cre expression and indirectly determine where 
Pot1a is being deleted, mice from the VCre, Pot1a colony were crossed with the 
Rosa26-LacZ (R26R) reporter transgene. Cre recombinase activity activates the 
reporter gene, which can be detected through β-galactosidase (β-gal) activity. 
Intestines were collected from animals of various genotypes and assayed for β-gal 
activity. Positive activity is indicated by blue staining. Intestines that did not express 
the VCre transgene (VCre-) and mice that were R26R negative did not show any β gal 
activity. In contrast, VCre+ R26R+ mice showed β-gal activity in both the small 
intestines and colons. Two animals were examined per genotype. 
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Figure 8: Villin-Cre activity is specific to the intestinal epithelium.  β-gal activity 
was assayed in various organs of VCre+ Rosa+ mice. No activity was seen in the heart, 
kidney, liver or stomach of these animals.  However, β-gal staining was readily visible 
in the small intestines and colon. Note that the staining in the Pot1aint∆ Rosa26+ 
intestines is less intense than in the control samples. Furthermore, there seem to be 
entire crypts that do not stain for β-gal at all (arrow). These results suggest that 
intestinal deletion of Pot1a may not be complete in the Pot1aint∆ animals. (Two 
animals for each genotype were examined.) 
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heart kidney 
liver stomach 
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examined. Comparison of hematoxylin and eosin (H&E) stained sections from Pot1aint∆ 
intestines to controls showed no villous blunting, no crypt atrophy, and no changes to the 
overall morphology of the intestines (Figure 10). 
 However, closer inspection revealed an increase in apoptotic cells in the crypts of 
Lieberkuhn (Figure 10), a characteristic that is seen in mice with telomere 
dysfunction(Begus-Nahrmann et al., 2009; Cosme-Blanco et al., 2007; Wong et al., 2000). 
Examination of 500 crypts per sample, comparing four animals per genotype, showed that 
there was an 8-fold increase in apoptotic bodies in the Pot1aint∆ animals compared to the 
VCre- controls (control: 0.076±0.057 vs. Pot1aint∆: 0.598±0.119, p = 0.001) (Figure 10). 
There was no significant difference between the VCre- and VCre+ controls, suggesting that 
the phenotype is due to Pot1a deficiency and not Villin-Cre expression. TUNEL staining was 
also performed to assay for apoptosis. Four animals per genotype were tested and 500 crypts 
per animal were examined. Quantification of TUNEL positive cells in the crypts revealed a 
15-fold increase in the intestines of Pot1aint∆ animals compared to the VCre- controls 
(control: 0.076±0.072 vs. Pot1aint∆: 1.22±0.08, p = 0.001) (Figure 11). 
Dysfunctional telomeres can be improperly repaired by the generation of random 
fusions through the non-homologous ending joining (NHEJ) or homologous recombination 
(HR) pathway forming dicentric chromosomes. During anaphase, migration of the dicentric 
chromosomes to opposite poles can be seen as an anaphase bridge. These are readily visible 
in H&E sections and are used as an indication of telomere dysfunction in highly proliferative 
compartments, including the intestinal epithelium (Cosme-Blanco et al., 2007; Rudolph et al., 
2001). To determine if Pot1a deletion leads to telomere dysfunction in our model, H&E 
sections were examined for anaphase bridges (Figure 12). The number anaphase bridges 
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Figure 9: Intestinal deficiency of Pot1a does not affect overall survival. Mice in 
the VCre, Pot1a colony were followed for up to 2 years. Kaplan-Meier analysis of the 
cohorts show that Pot1aint∆ mice survived at a rate comparable to controls.  
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Figure 10: Loss of Pot1a does not affect the gross morphology of the intestinal 
epithelial, but increases apoptosis in crypts. Examination of H&E staining of 
intestines from 1-year old VCre, Pot1a animals showed that there is no appreciable 
difference in gross morphology. Closer examination of the intestinal crypts revealed 
that Pot1aint∆ animals have an increase in apoptotic bodies. Quantification showed 
that there is 8-fold increase in apoptotic bodies in the Pot1aint∆ compared to the VCre- 
controls (0.076±0.057 vs. 0.598±0.119, p = 0.001). Intestines from four animals per 
genotype were examined, and 500 crypts per animal were analyzed. 
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Figure 11: Pot1a deficiency leads to increased TUNEL positive cells in the 
intestinal crypts. TUNEL was performed on intestinal samples to detect apoptosis. 
TUNEL positive cells (arrows) were only detected in the intestines of Pot1aint∆ 
animals. Furthermore, the increase in TUNEL positive cells was restricted to the 
crypts. No appreciable increase was seen in the villi. Intestines from four animals per 
genotype were examined, and 500 crypts per animal were analyzed.   
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Figure 12: Anaphase bridges are a hallmark of telomere dysfunction. 
Dysfunctional telomeres can lead to chromosomal fusions that can be visualized as 
anaphase bridges. The upper panel shows a normal anaphase (single arrow) and 
several examples of anaphase bridging (double-line arrows). Quantification of the 
anaphase bridges in Pot1aint∆ mice show a 2.5 fold increase in ABI as compared to 
VCre- (0.258±0.008 vs. 0.093±0.023). Intestines from four animals per genotype were 
examined, and 500 crypts per animal were analyzed.     
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observed was divided by the total number of anaphase seen to determine the anaphase bridge 
index (ABI). Quantification of the anaphase bridges in Pot1aint∆ mice show a 2.5 fold 
increase in ABI as compared to VCre- (0.258±0.008 vs. 0.093±0.023, respectively; p=0.002) 
(Figure 12).  
Taken together, these results indicate that while Pot1aint∆ mice do not show the same 
overt intestinal degeneration, Pot1a deficiency leads to phenotypes in the crypts of 
Lieberkuhn that recapitulate those observed in telomerase null animals with critically 
shortened telomeres, including increased apoptosis and anaphase bridges.  
 
Pot1a deficiency leads to increased activation of p53 and p21  
Similar to severe telomere attrition, loss of Pot1a activates a potent DNA damage 
response that triggers p53-dependent cellular senescence in cell culture(Wu et al., 2006). p53 
is also a potent inducer of apoptosis in mouse models of telomere shortening(Chin et al., 
1999). To determine if loss of Pot1a also activates p53 in our model, IHC was performed on 
paraffin-embedded intestine sections (Figure 13). Comparison of four animals per genotype 
and 500 crypts per animal revealed that intestines from Pot1aint∆ mice show a 10-fold 
increase in p53 positive cells as compared to VCre- controls (Pot1aint∆, 0.362±0.068; VCre-: 
0.003±0.0008; t-test, p=0.006). In fact, little to no p53 staining was seen in either VCre- or 
VCre+ controls, again confirming that these phenotypes are due to loss of Pot1a instead of 
Villin-Cre expression.  
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Figure 13: Loss of Pot1a activates p53 in the intestinal crypts. p53 is a major 
mediator of apoptosis that is also activated in response to telomere dysfunction. IHC 
staining for p53 was performed to determine if this response could be observed. Cells 
staining positively for p53 (arrows) were seen almost exclusively in the intestinal 
crypts of the Pot1aint∆ mice. Intestines from four animals per genotype were examined, 
and 500 crypts per animal were analyzed.  
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p21 is potent inducer of cell cycle arrest during cellular senescence triggered by 
telomere attrition(Herbig et al., 2004) and Pot1a loss in cultured cells (Wu et al., 2006). p21 
is also a downstream target of p53 that is also activated in response to telomere dysfunction 
in late generation telomerase null mice(Choudhury et al., 2007). IHC to assay for p21 
expression was performed to determine if the increased expression of p53 seen above also 
leads to upregulation of p21 (Figure 14). Indeed, intestines from Pot1aint∆ mice show an 8-
fold increase in p21 expression over VCre- controls (3.98±1.08 vs. 0.54±0.15, respectively; t-
test; p = 0.006). Four mice from each cohort were examined and 500 crypts from each 
sample were analyzed.  
These results indicate that Pot1a deficiency leads to the activation of p53 and its 
downstream effector, p21. Taken together with the previous section, these data suggest that 
loss of Pot1a activates p53 leading to apoptosis or p21 activation and senescence, similar to 
cells and mice with severe telomere attrition or Pot1a deficient cells (Figure 4).  
 
Loss of Pot1a leads to activation of a telomere-induced DNA damage response 
Pot1a binds to the single-stranded G-rich telomeric overhang to protect it from 
activating a DNA damage response mediated by ATR(Denchi and de Lange, 2007; Guo et 
al., 2007). Loss of Pot1a is thought to expose the overhang to RPA binding, which recruits 
ATR/ATRIP. These proteins trigger the DDR pathway by phosphorylating and recruiting 
factors like the phosphorylated histone variant H2AX (γ-H2AX), the mediator of DNA 
damage checkpoint1 (MDC1), and p53 binding protein 1 (53BP1)(Shiloh, 2003). These 
proteins accumulate at the sites of damage and along the surrounding chromatin, and can be 
readily visualized through fluorescence microscopy as DNA damage foci. To assess damage 
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Figure 14: Loss of Pot1a leads to upregulated p21 expression in the 
intestines. p21 is a downstream target of p53 and is thought to be involved in 
triggering senescence in response to telomere dysfunction. IHC of intestinal 
sections show an increase in p21 positive nuclei (arrows) in Pot1aint∆ crypts. 
Quantification (graph) reveals almost an 8-fold increase in p21 expression in 
mice that have lost Pot1a. Intestines from four animals per genotype were 
examined, and 500 crypts per animal were analyzed.   
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signaling at telomeres, an invaluable experimental tool based on this property has been used 
extensively. Telomere-induced damage foci (TIFs)(Takai et al., 2003) are fluorescently-
labeled DNA damage protein markers, such as γ-H2AX or 53BP1, that co-localize to 
dysfunctional telomeres, which are also marked by fluorescently-labeled telomeric nucleotide 
probes or shelterin proteins. We assayed for TIFs in paraffin-embedded tissues through 
double immunofluorescent staining for γ-H2AX (green) and the telomere binding protein, 
mTRF2 (red) (Figure 15). Sections were examined through fluorescence or confocal 
microscopy. Nuclei with three or more co-localized foci were scored as TIF positive. 
Examination of intestinal sectionals revealed that TIF positive cells were found exclusively 
in the crypts of Lieberkuhn; no TIFs were seen in the villi (Figure 16). Comparison of the 
different cohorts showed that TIF positive cells were found mostly in Pot1aint∆ crypts, which 
had 10-fold more TIF positive cells than VCre- controls (26.4 ± 7.4 vs. 2.2 ± 0.8 TIF positive 
cells per 100 nuclei, respectively; t-test; p=0.005). These results indicate that deletion of 
Pot1a elicits a DNA damage response in the intestinal crypts.  
 
Intestinal Pot1a deficiency does not affect response to gamma-irradiation 
The results above have shown that loss of Pot1a induces a DNA damage response in 
the intestinal epithelium leading to increased cell cycle arrest and apoptosis. Although these 
features do not appear to lead to degenerative phenotypes, we postulated that chronic DNA 
damage may have an effect on the stem cell reserve of the intestines. To determine whether 
this mechanism of telomere dysfunction has an effect on the regenerative capacity of the 
intestines, we subjected mice in the Villin-Cre, Pot1a colony to whole body gamma 
irradiation (IR), which would deplete the epithelial layer. 
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Figure 15: Loss of Pot1a activates a DNA damage response in the intestines. 
Telomere-induced damage foci (TIFs) are formed when markers of DNA damage, 
such as γ-H2AX (green) colocalize to sites of dysfunctional telomeres (marked by 
mTRF2 (red)). Cells with three or more foci are considered TIF positive. Double IF 
staining of intestinal sections demonstrate that Pot1aint∆ crypts contain ten-fold more 
TIF positive cells than controls. Intestinal crypts from four animals per genotype 
were examined, and 1000 nuclei per animal were analyzed.  
p = 0.005 
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Figure 16: DNA damage is only observed in cells of the crypts. Double IF staining 
of intestinal sections to assay for telomere-induced damage foci (TIFs). γ-H2AX 
serves as a marker of DNA damage (green), while mTRF2 serves as a marker for 
telomeres (red). The left panel shows pictures of a villus, while the right panel shows 
crypts. Several TIF positive cells are indicated by white arrow. 
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In the first experiment, two groups of 10-week old mice were subjected to whole 
body IR. At a dose 4Gy, there seemed to be no difference between the responses of the two 
genotypes as all the animals survived more than 40 days (Figure 17, solid lines). Next, we 
increased the dose and exposed a second set of 10-week old animals to a higher dose of 
radiation (8Gy). This dose proved to be lethal as animals in both cohorts did not survive for 
more than three weeks after exposure. A comparison of the survival curves showed that there 
was no significant difference between survival among animals that were deficient in Pot1a 
compared to wild-type (Figure 17, dashed lines).  
One possible reason for the lack of difference may be the age of the mice. Despite the 
increased apoptosis that would put a strain on stem cell reserve, perhaps the intestines of 10-
week old animals have not been challenged enough by the telomere dysfunction to 
significantly deplete the reserve of such a proliferative organ. The experiment was repeated 
in animals that were aged to one year. These mice were exposed to a 6Gy dose of radiation. 
Similar to previous results with a 4Gy dose, all the animals survived longer than 40 days 
(Figure 18A). Surprisingly, comparison of the intestinal morphology of animals at one and 
four days after radiation exposure also did not show any significant difference (Figure 18B). 
These results suggest that the Pot1aint∆ mice responded to radiation in a similar fashion as the 
wild-type controls. 
 
Discussion 
We sought to create a mouse model of telomere dysfunction in the gastrointestinal 
tract through the targeted deletion of Pot1a. To achieve this, we crossed a conditional Pot1a 
knockout mouse with the Villin-Cre transgenic mouse that only expresses the Cre  
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Figure 17: Pot1a deficiency in the intestines does not affect survival of 3-month 
old animals after irradiation. Whole body irradiation was given at a dose of 4Gy to 
3-month old animals. The treatment did not affect survival of control or Pot1aint∆ mice 
(solid lines) as they all survived for over 40 days. When the dose was increased to 
8Gy, none of the irradiated animals survived longer than 3 weeks. However, there was 
no significant difference between the survival of the Pot1aint∆ mice as compared to 
control mice (dashed lines). 
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Figure 18: Pot1a deficiency does not affect intestinal response to irradiation. One 
year old animals were exposed to 6Gy of γ-irradiation (n=6 for both groups). All 
animals survived at least 40 weeks (Panel A). Intestines of one year old mice exposed 
to 6Gy doses of irradiation were examined one and four days after treatment (Panel 
B). Surprisingly, analysis of H&E staining shows little effect on the intestines at both 
time points, irrespective of Pot1a status. 
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 recombinase in the GI tract. Our data show that despite the fact that loss of Pot1a in cell 
culture is toxic,  leading to cellular senescence, mice with homozygous loss of Pot1a in the 
intestines (Pot1aint∆) were viable and born at expected the expected Mendelian ratios. Pot1a 
deletion was verified indirectly through genomic PCR. However, the appearance of the delta 
band did not correlate with the disappearance of the floxed band. This result may be 
explained by the fact that Villin-Cre is only expressed in the epithelial layer, as demonstrated 
by the X-gal staining. There are many different cell types in the intestines in addition to the 
epithelial layer, including the surrounding stromal cells that support the epithelium, 
endothelial cells that make up the capillaries and lymphatic vessel in each villus, and 
lymphocytes. Although intestinal scrapings were performed to enrich epithelial cells from the 
supporting submucosa and muscle wall, these other cells could not be separated and may 
contribute to the amplification of the flox band. 
Interestingly, X-gal staining in VCre, Pot1a, R26R+ mice demonstrated that Cre 
activity was restricted to intestinal epithelial cells. However, qualitative comparisons of 
staining suggested that β-gal activity was not equal in Pot1aint∆ R26R+ mice as compared to 
VCre+ R26R+ controls. The staining was in fact weaker throughout the crypt-villus axis in 
Pot1aint∆ intestines, and some crypts did not stain for X-gal at all. This result may prove to be 
significant as it suggests that Pot1a may not be completely deleted in these intestines.   
  The VCre, Pot1a colony was followed for over two years, and there was no difference 
in overall survival between mice with Pot1a loss and controls. Comparison of intestinal 
morphology also revealed no appreciable difference in gross morphology. However, closer 
examination revealed that loss of Pot1a leads to various microscopic changes in the intestinal 
epithelium. Pot1a deletion leads to increased apoptotic cells in the crypts, as well as 
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upregulation of p53 and p21 expression. Finally, Pot1a deletion leads to increased cells with 
TIFs, an indicator of activation of the DDR in response to dysfunctional telomeres. These 
data correspond to previous work in cell culture, which has shown that deletion of Pot1a 
leads to a DNA damage response, which activates p53 to trigger cell cycle arrest through p21 
or apoptosis(Wu et al., 2006). Late generation telomerase null animals with critically short 
telomeres have also shown the same features in intestinal crypts(Choudhury et al., 2007; 
Rudolph et al., 1999). Taken together, we have generated a model of telomere dysfunction 
through Pot1a disruption in the gastrointestinal tract that has similar microscopic features as 
mouse models of telomere attrition.  
However, our model does not show the overall morphological features of critical 
telomere shortening, such as blunting or atrophy of villi(Rudolph et al., 1999). The β-gal 
staining result on the reporter mice may provide some insight to this result. Given the 
apoptosis results, one possible explanation is that Pot1a deficient cells are being culled from 
the crypts through p53-dependent apoptosis, while the cells that have retained some Pot1a 
expression due to incomplete deletion of the two conditional alleles or complete inactivation 
of the Cre recombinase are populating the villi. This phenotype has been described 
previously in mice that have intestinal specific Mdm2-deficiency(Valentin-Vega et al., 
2008). Mdm2 is a potent inhibitor of p53, and its loss in mice leads to p53-dependent 
apoptosis and consequently embryonic lethality(Montes de Oca Luna et al., 1995). Even 
conditional deletion of Mdm2 in tissues, such as the heart and nerve cells, cannot produce 
viable animals(Grier et al., 2006; Xiong et al., 2006). However, the intestine is able to 
compensate for such toxic insults by selecting for cells that have lost the VCre transgene and 
have intact Mdm2 activity(Valentin-Vega et al., 2008). It is possible that our model is 
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behaving similarly to the Mdm2, with the cells that have lost or reduced Cre expression 
surviving to populate the villi and prevent degenerative phenotypes.  
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THE EFFECT OF POT1A DEFICIENCY ON ESTABLISHED MOUSE MODELS OF 
GI TUMORS 
Because of the potent DNA damage response that is elicited in response to Pot1a 
deficiency and the subsequent activation of p53, p21 and apoptosis in the intestines of the 
VCre, Pot1a animals, we postulate that loss of Pot1a will be tumor suppressive in vivo. The 
mTerc null mouse has been used in multiple cancer models to show that critically short 
telomeres are tumor suppressive(Cosme-Blanco et al., 2007; Farazi et al., 2003; Feldser and 
Greider, 2007; Gonzalez-Suarez et al., 2000; Greenberg et al., 1999; Khoo et al., 2007; 
Rudolph et al., 2001; Wong et al., 2003) (Table 2). For example, late generation telomerase 
null mice are resistant to skin tumors induced by the DMBA/TPA chemical skin 
carcinogenesis model(Gonzalez-Suarez et al., 2000). Also, in the APCmin intestinal 
carcinoma mouse model, mice with critically short telomeres showed improved survival with 
a decrease in macroscopic adenoma formation compared to mice with intact 
telomeres(Rudolph et al., 2001). To determine if loss of Pot1a in the intestines is also tumor 
suppressive, we combined our Villin-Cre, Pot1a mouse with two separate models of 
intestinal cancer: the APCmin mouse or the chemical colitis-induced model of colorectal 
cancer.   
 
The effect of Pot1a-induced telomere dysfunction on the APCmin genetic model of 
intestinal tumorigenesis 
Mutations in the adenomatous polyposis coli (APC) gene are responsible for 
intestinal tumor syndrome called familial adenomatous polyposis (FAP) and found in 34- 
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Table 2: Shortened telomeres (Terc-/-) reduce tumor incidence in mouse models of 
cancer 
 
Gene or 
treatment Tumor phenotypes Effect of dysfunctional telomeres Ref. 
APCmin Multiple intestinal 
neoplasia (MIN). 
increase in (microadenomas) 
decreased size and number of 
macroadenomas 
Rudolph, Millard 
et al. 2001 
Alb-uPA hepatocellular 
carcinoma (HCC) decreased number and size of liver nodules. 
Farazi, Glickman 
et al. 2003 
PMS2 
Lymphomas, 
sarcomas, and  
colon carcinomas 
reduced the incidence of all three tumors 
types. 
Siegl-Cachedenier, 
Munoz et al. 2007 
Em-myc Burkitt’s lymphoma. 
Formation of lymphoma was almost 
completely suppressed for two years in mice 
with dysfunctional telomeres (G5/G6) 
Feldser and 
Greider 2007 
ATM Thymic lymphoma Delayed onset and decreased incidence of thymic lymphomas 
Qi, Strong et al. 
2003; Wong, 
Maser et al. 2003 
DMBA/TPA 
Treatment 
Squamous cell 
carcinomas (SCC)  
of the skin 
Decreased growth rate and size of 
papillomas, with a slight decrease in 
numbers. G5 mice with dysfunctional 
telomeres were almost completely  
Resistant to papilloma formation. 
(Gonzalez-Suarez, 
Samper et al. 
2000) 
CCl4 or DEN 
treatment 
Hepatocellular 
carcinoma (HCC) Decreased number and size of liver nodules. 
(Farazi, Glickman 
et al. 2003) 
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72% of sporadic colorectal cancer(Takayama et al., 2006). In the APCmin mouse model, loss 
of the wildtype copy of the APC allele results in mice with multiple intestinal neoplasia, at 
100% penetrance. Previous results from the mTerc-/-, APCmin mouse, showed that critically 
short telomeres improved overall survival of these mice by suppressing the progression of 
microadenoma to macroadenoma, and impairment of macroadenoma growth(Rudolph et al., 
2001). This is thought to be due to telomere-induced p53-dependent apoptosis or senescence, 
as the anaphase bridge index, p53 staining and apoptotic index is all increased in the late 
generation mutant mice(Rudolph et al., 2001). To determine if telomere dysfunction due to 
loss of Pot1a will have the same effect, the Villin-Cre, Pot1a mice were crossed with the 
APCmin mice to produce the following three cohorts: VCre- APCmin, VCre+ APCmin, and 
Pot1aint∆ APCmin.  
These mice were followed and monitored for signs of intestinal tumor burden, 
including abdominal distention, anemia, cachexia and rectal prolapse. Moribund animals 
were euthanized and intestines were harvested and examined. Tumors were mostly round 
sessile adenomas, and the size (longest dimension) and number were noted. Animals 
developed between 29 and 76 tumors, and ranged in size from 1mm to 6mm. To simplify 
quantitation, tumors were divided into three size categories: less than 2mm, 2-4mm, and 
greater than 4 mm. Comparison of the three cohorts revealed that there was no significant 
difference in the number of tumors formed in each size category, nor in the total number of 
found (Figure 19, Table 3).  These results suggest that unlike late generation telomerase null 
mice, Pot1a deficiency is not tumor suppressive. 
Since telomere dysfunction due to Pot1a loss did not affect tumor formation, we 
examined the histological features of the tumors formed in each cohort to determine if there  
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Figure 19: Loss of Pot1a does not affect the number or size of tumors in APCmin. 
The number and size of tumors found in the intestines of mice from the various Pot1a, 
APC cohorts were recorded on dissection of moribund animals. Tumors from the 
small intestine were divided into three size categories, while the few colon tumors that 
formed were lumped together. Comparison of the cohorts revealed no significant 
difference between the total number or predominant sizes of tumors found in each 
cohort. 
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Table 3: Summary of average tumors burdens for each cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
54.2 ± 18.7 58.8 ± 11.4 46.5 ± 14.4 total 
1.5 ± 1.5 1.5 ± 1.3 1.7 ± 1.2 Colon 
6.7 ± 3.5 11.8 ± 5.1 6.7 ± 3.8 > 4mm 
19.5 ± 11.1 22.0 ± 5.6 15.2 ± 6.2 2 – 4mm 
27.3 ± 10.4 23.5 ± 8.6 23.0 ± 14.0 < 2mm 
Pot1aint∆ 
APCmin/+ 
VCre+ APCmin/+ VCre- APCmin/+ Cohort/ 
Tumor size 
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Figure 20: Pot1a loss does not affect the tumor type or grade in APCmin mice. 
Comparison of H&E staining of intestinal sections from Pot1aint∆ APCmin and APCmin 
mice reveal no histological differences between the two groups. Both develop well-
differentiated adenomas with no invasion. Areas of tumors are outlined by red-dashed 
line. 
 
APCmin Pot1aint∆ APCmin 
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was a difference in the type or grade of tumor formed. H&E staining of paraffin embedded 
sections revealed that mice from all three cohorts developed benign well-differentiated 
adenomas. There were no signs of invasion or metastasis, and overall no significant 
histological difference appreciated between tumors from Pot1aint∆ APCmin mice and controls 
(Figure 20). This result suggests that Pot1a deficiency does not affect the grade of tumor that 
is formed in the APCmin background.  
While Pot1a deficiency did not affect the type and grade of tumor formed, it appeared 
to have an effect on overall survival. Kaplan-Meier analysis of overall survival was 
performed (Figure 21) and Pot1aint∆ APCmin mice showed a significant reduction in lifespan, 
with a median survival of 16.3 weeks and compared to 25 weeks in control VCre- APCmin 
mice (t-test, p = 0.0012). This result suggests that loss of Pot1a leads to decreased survival in 
the APCmin colony.  
Since there was no appreciable difference between the tumor burden for each cohort 
at death, we hypothesized that perhaps tumor formation was occurring earlier in Pot1aint∆ 
APCmin/+ mice. To determine if this was the case, we surveyed five mice from the VCre- 
APCmin/+ and the Pot1aint∆ APCmin/+cohorts at an early timepoint (12 weeks) for tumor 
formation. The number of tumors visualized on dissection was noted and categorized by size 
for each animal as described above (Figure 22A). Statistical analysis of each size category 
revealed that while the total number of tumors was not significantly increased in Pot1aint∆ 
APCmin/+ mice, these mice did have larger tumors at earlier timepoints (Figure 22B). These 
data suggest that the reason for decreased survival in Pot1aint∆ APCmin/+ mice is that Pot1a 
deficiency accelerates tumor formation in the APCmin background.    
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Figure 21: Intestinal depletion of Pot1a leads to decreased overall survival in 
APCmin mice. The VCre, Pot1a mice were crossed with APCmin mice to determine the 
affect of loss of Pot1a on this mouse model of intestinal tumorigenesis. Surprisingly, 
Pot1aint∆ APCmin (red line) leads to earlier death than VCre- APCmin controls (black 
line), with a median life span of 16.3 weeks vs. 25.0 weeks, respectively. VCre+ 
controls (blue line) showed no significant difference when compared to VCre- 
controls. (n=27 animals for VCre- APCmin; n=12 for VCre+; and n=20 for Pot1aint∆ 
APCmin.) 
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Figure 22: Pot1aint∆ APCmin animals form large tumors earlier than control mice. 
To determine why Pot1aint∆ APCmin animals died earlier than control mice, five mice 
from each cohort were examined for tumor formation at 12 weeks of age. Panel A 
shows the number and size of tumors found in each mouse that was examined. Tumors 
were mostly round sessile polyps and size was determined by longest dimension. A 
statistical comparison of the number of tumors stratified by size showed that 
Pot1aint∆ APCmin mice had more medium (2-4mm) and large (>4mm) tumors at 13-
weeks than control.    
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To gain some insight as to why tumor formation was accelerated, we examined the 
histological features of the 12 week old mice through H&E staining. Comparison of 
apoptotic bodies in VCre-, VCre+ and Pot1aint∆ APCmin/+ mice revealed a 7.5-fold increase in 
apoptosis in the intestinal crypts of Pot1aint∆ APCmin/+ mice as compared to VCre- APCmin/+ 
controls (0.75±0.11 vs. 0.10±0.05, respectively; t-test, p>0.001) (Figure 23A). We further 
examined the intestines for the presence of anaphase bridges. There was a modest 1.5 fold 
increase in anaphase bridge index in the Pot1aint∆ APCmin/+ crypts as compared to controls 
(Pot1int∆: 0.017±0.02; VCre-: 0.08±0.02; t-test; p = 0.002) (Figure 23B). The increased 
anaphase bridges suggest that there may be increased genomic instability in APCmin 
intestines that are deficient in Pot1a, possibly contributing to increased apoptosis.  
 
Discussion 
The data described above indicate that our model of Pot1a deficiency is not tumor 
suppressive. Instead, telomere dysfunction caused by uncapping appears to accelerate tumor 
initiation as evident by the heavier tumor burden in young animals and decreased survival of 
the Pot1aint∆ APCmin/+ cohort as compared to VCre- and VCre+ APCmin/+ controls. These 
results are in contrast to what was seen in late generation telomerase null mice, where 
telomere dysfunction from severely shortened telomeres acted to suppress tumor 
formation(Rudolph et al., 2001). This may be due to telomere-induced genomic instability 
driving LOH of the APC allele faster than in wild-type controls, as the mutant intestines 
show an increase in anaphase bridging. While the concurrent increase in apoptosis may 
suggest that tumor suppression should occur, perhaps this increased turnover combined with  
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Figure 23: Pot1aint∆ APCmin have increased apoptosis and anaphase bridges. Five 
mice from each cohort were examined at 12 weeks of age (500 crypts per animals). 
(A) Quantification of apoptotic bodies. (B) Quantification of the number of anaphase 
bridge index (# anaphase bridges over total anaphases).    
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genomic instability shortens the time needed for generation and selection of cells with 
cancer-promoting genomes.  
The combination of telomere-induced genomic instability with the tumor-initiating 
power of the APCmin mutation in the intestinal epithelium, suggests that it might be a good 
 model for promoting tumor progression. Unfortunately, the accumulation of the appropriate 
genetic alterations to promote progression is a stochastic process that requires time. The 
overwhelming tumor burden of this model prevented the animals from surviving long enough 
to determine if that process could occur. 
  
The effect of loss of Pot1a on a colitis-induced model of colorectal cancer 
The APCmin model mainly produces tumors in the small intestine. To examine the 
effect of loss of Pot1a in the colon, we used a model of chemically induced colon cancer that 
combines the chemical carcinogen azoxymethane (AOM) and dextran sodium sulfate (DSS) 
induced colitis(Neufert et al., 2007). While there are different versions of this protocol with 
varying doses of AOM and DSS(Suzuki et al., 2006; Tanaka et al., 2003), we chose to follow 
the protocol outlined in Figure 24(Neufert et al., 2007). Briefly, 10-15 week old VCre, Pot1a 
animals from each cohort were treated with a single injection of AOM (10mg/kg body 
weight). Immediately after the injection, the mice were fed a one week course of 3% DSS 
water, followed by two weeks of regular water. This was repeated two more times for a total 
of three cycles.  
Under this protocol, we expected VCre- wild-type animals to develop multiple large 
tumors in the colon by 10 weeks (Becker et al., 2005), therefore tumor evaluation was 
performed at this timepoint. However, our cohorts showed very little tumor formation,  
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Figure 24: Protocol for AOM/DSS experiment. The protocol for the chemically 
induced colon carcinogenesis model is outlined in the figure above. At Day 0, mice 
are injected with azoxymethane (AOM) at a concentration of 10mg/kg. A regular diet 
was supplemented with 3% dextran sodium sulfate (DSS) water instead of tap water 
for a period of one week. Mice were fed regular tap water for two weeks following 
DSS treatment. This 3-week cycle was repeated for a total of three times. Mice were 
euthanized at 10 weeks to evaluate tumor formation. 
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Table 4: Tumor formation in mice treated with AOM/DSS at 10-weeks 
 
Genotype # animals # tumors 
VCre- 26 3 
VCre+ 14 0 
Pot1aint∆ 16 0 
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including the VCre- control cohort in which only three tumors were found, one 
macroscopically on dissection and two additionally upon histological analysis (Table 4). The 
lack of tumor formation in the control mice led us to consider this a failed experiment.  
Previous studies have demonstrated the strain differences can affect the susceptibility of mice 
 to this protocol(Suzuki et al., 2006). Our mice have a mixed background of C57Bl/6 and 
129Sv. C57Bl/6 strain is not very susceptible to AOM treatment alone, moderately 
susceptible to the combined treatment(Suzuki et al., 2006). We considered the possibility that 
the genetic background of our mice was a barrier to tumor formation using this model. 
Another possible explanation is that because of the inherent strain resistance to the 
treatment, tumor formation occurs after a longer latency in our mice than other strains. To 
test this theory, the protocol was repeated with another cohort of mice. In this experiment, 
tumor evaluation was performed at 15 weeks instead of 10 weeks. Tumors were seen in mice 
from this experimental cohort, but they were still few in numbers and most were very small 
(<2mm) (Figure 25A). Quantification of tumor number showed no significant difference in 
tumor formation in the VCre- control mice as compared to Pot1aint∆ mice (4.75±3.4 vs. 5.13± 
2.7, respectively; t-test; p=0.81)(Figure 25B). Therefore, Pot1a deletion does not appear to 
suppress tumor formation in this model. However, future experiments may include delaying 
tumor evaluation for a longer period (greater than 20weeks) to determine if telomere 
dysfunction has an effect on tumor growth and progression in this model. The low 
multiplicity makes the tumor burden easier for the mice to bear, and longer timepoints that 
cannot be achieved in the APCmin model may be studied in the AOM/DSS model. 
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Figure 25: Tumor formation in mice treated with AOM/DSS at 15 weeks. The 
AOM/DSS protocol for chemically inducing colon carcinogenesis was repeated. Eight 
animals of each genotype were treated with the same protocol, but tumor evaluation 
was conducted at 15 weeks, instead of the previous endpoint of 10 weeks. At this later 
time point, more tumors were visualized in the colons of the treated animals (Panel A; 
white arrows). Most of these tumors were less than 2mm in size. A comparison of the 
tumors found in the two cohorts (Panel B) showed that there was no significant 
difference in the number of tumors formed in the control vs. the Pot1aint∆ mice 
(p=0.81). 
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COMBINED LOSS OF POT1A AND P53 LEADS TO TUMOR FORMATION 
p53-dependent activation of p21 and apoptosis serves as a potent checkpoint to stop 
propagation of cells with dysfunctional telomeres. Therefore, p53 activity is a key barrier that 
keeps dysfunctional telomeres acting in a tumor suppressive fashion and prevents the 
transition to telomere dysfunction driving genomic instability and tumor formation. The 
importance of this checkpoint was demonstrated in the telomerase null mouse model(Chin et 
al., 1999), where p53 deficiency rescued or delayed many of the degenerative phenotypes 
seen in late generation mTerc-/- mice, such as testicular atrophy and bone marrow failure. 
Telomerase null animals that are deficient in p53 develop tumors(Artandi et al., 2000), 
further confirming the importance of this checkpoint for tumor suppression. In fact, 
dysfunctional telomeres in this case cooperate with p53 loss to form tumors, and 
interestingly, the combination shifts the tumor spectrum from lymphomas and sarcomas to 
carcinomas of the breast and gastrointestinal tract(Artandi et al., 2000). p53 deficiency also 
allows Pot1a null cells to bypass senescence(Wu et al., 2006). Furthermore, injection of 
immortalized Pot1a and p53 double deficient cells into SCID mice produces tumors(Wu et 
al., 2006). Based on these data, we hypothesized that abrogation of p53 in our Villin-Cre, 
Pot1a mice would allow tumor formation in the gastrointestinal tract.  
To generate mice with intestinally deleted Pot1a and p53, we crossed the Villin-Cre, 
Pot1a mice with a mouse that contains conditional p53 alleles that are also flanked by loxP 
sites(Jonkers et al., 2001). The following cohorts were created for analysis: Pot1aint∆ p53+/+; 
Pot1aint∆ p53F/+; Pot1aint∆ p53F/F; and finally p53F/F, which represents mice with only p53 
deleted in the intestines. To determine p53 deletion, we employed a PCR strategy developed 
by the Berns lab for this allele(Jonkers et al., 2001). Analysis of DNA from several tissues 
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demonstrated that deletion of Pot1a and p53 were both still restricted to the small intestines 
and colon (Figure 26).  
 
Apoptosis and p21 activation in Pot1a intestines is p53-dependent 
Two of the main microscopic features seen in Pot1aint∆ mice are upregulation of p21 
and increased apoptotic cells in the crypts. Concurrent upregulation of p53 and the 
importance of the p53 checkpoint in the response to dysfunctional telomeres suggest that 
these phenotypes are p53-dependent. Comparison of the presence of apoptotic bodies (Figure 
27A) in the intestines of the various cohorts revealed that loss of one allele of p53 lead to a 
slight but significant decrease in apoptosis (Pot1aint∆ p53+/+: 0.559±0.042 vs. Pot1aint∆ p53F/+: 
0.399 ± 0.033, t-test, p = 0.006). Loss of both p53 alleles led to almost complete rescue of the 
phenotype with a 4.5-fold decrease in apoptosis (0.123 ± 0.04; t-test, p = 0.0002). Similarly, 
upregulation of p21 was also completely abrogated in the setting of p53 deficiency (Figure 
27B). These results confirm that the activation of p21 and apoptosis in response to Pot1a loss 
are p53-dependent processes. 
 
p53 deficiency allows for more cells with telomere dysfunction to persist 
With cell cycle arrest and apoptosis abrogated in p53 deficient animals, we sought to 
determine how this affects the cells with telomere dysfunction. Double IF staining to assay 
for TIFs in the intestines revealed that p53 deficiency leads to an increase of TIF positive 
nuclei in the crypts (Pot1int∆p53+/+: 0.27±0.05 vs. Pot1int∆p53F/F: 0.57±0.13; t-test; p=0.02) 
(Figure 28). These results suggest that in the absence of a clearing mechanism, such as  
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Figure 26: Verification of Pot1a and p53 deletion in Pot1aint∆ p53F/F mice. Using 
primers can detect deletion of the Pot1a and p53 alleles, PCR analysis of genomic 
DNA isolated from various organs of Pot1aint∆ p53F/F mice show that both genes are 
indeed being deleted only in the intestines. 
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Figure 27: Apoptosis and p21 activation in Pot1aint∆ intestines is p53-dependent. 
Comparison on apoptotic bodies on H&E sections of mice from the VCre, Pot1a, p53 
mouse colony show that while p53 haploinsufficiency partially decreases the 
apoptosis in Pot1aint∆ mice, complete p53 deficiency rescues the phenotype to control 
levels (Panel A). Similarly, p21 IHC reveals that p53 deficiency abrogates activation 
of this pathway in Pot1aint∆ mice (Panel B). Intestines from four animals per genotype 
were examined, and 500 crypts per animal were analyzed.   
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Figure 28: p53 deficiency leads to increased numbers of cells with telomere 
dysfunction. A tissue TIF assay was performed through double IF, using γ-H2AX 
(green) as a marker for DNA damage, and mTRF2 as a marker for telomeres (red). 
Nuclei with three or more foci of colocalization were counted as TIF positive. The top 
panel contains representative images of TIF positive nuclei from Pot1aint∆ p53F/F mice. 
Quantification of intestines from the different cohorts show that loss of p53 leads to an 
increase in cells with dysfunctional telomeres in the intestinal crypts. Three mice for 
each genotype were examined, and 1000 nuclei from each sample were analyzed.  
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apoptosis, cells with telomere dysfunction are allowed to persist and accumulate in the crypts 
of the mutant mice.    
 
Mice with combined Pot1a and p53 loss develop invasive adenocarcinomas   
Villin-Cre, Pot1a, p53 mice that were allowed to age developed intestinal tumors. 
Pot1aint∆ p53F/F mice form tumors in the gastrointestinal tract with almost 100% penetrance 
(Table 5). Tumor formation had a long latency, mostly appearing after 15 months of age. 
Tumors formed in low multiplicity, with most mice bearing only 1-4 tumors.  Pot1aint∆ p53F/+ 
mice also developed tumors but longer latency and lower penetrance. This is presumably due 
to spontaneous LOH of p53. Meanwhile, p53F/F only animals did not form any tumors in the 
gastrointestinal tract, suggesting that this process is driven by the combination of p53 
deficiency and telomere dysfunction; and loss of p53 is not enough to drive tumorigenesis in 
the intestines.  
Tumors had two different appearances: cecal masses were rounded polypoid masses 
that protrude into the lumen of the cecum (Figure 29A), while tumors found in the small 
intestine and colon tended to be flat annular rings, with beaded up borders and depressed 
centers (Figure 29B). The flat tumors were difficult to distinguish between irregular 
epithelium overlying lymphocytic aggregates (Peyer’s patches) in the intestinal walls, which 
looked similar. All tissue taken for further analysis was first confirmed histologically. 
Examination of the tumors revealed lesions that ranged from microscopic benign adenomas 
to well-differentiated adenocarcinomas that invaded into the submucosa, with some as far as 
the muscular wall (Figure 29C). While there was deep invasion into the muscle wall, no 
metastasis was observed in any of the animals.  
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Table 5: Combined Pot1a and p53 deficiency leads to tumor formation 
 
Genotype Age range 
Animals with 
tumors 
Multiplicity 
Size range 
(longest dimension) 
Pot1aint∆ p53+/+ 12-24 months 0/15 na Na 
Pot1aint∆ p53F/+ 
12-15 months 
15-18 months 
18-24 months 
1/7 
1/6 
3/8 
4 
2 
1 
micro 
2mm 
3mm 
Pot1aint∆ p53F/F 
12-15 months 
15-18 months 
18-24 months 
3/8 
7/8 
3/3 
1-2 
1-3 
1-3 
2-6mm 
4-15mm 
3-6mm 
p53F/F 
12-15 months 
15-18 months 
18-24 months 
0/5 
0/6 
0/3 
na n.a. 
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Figure 29: Combined loss of Pot1a and p53 leads to formation of invasive cancers 
in the GI tract. (A) Gross photo of round polypoid cecal tumor.  (B) Gross picture of 
two small intestine tumors that are flat with raised borders and depressed centers (red 
dashed lines). (C) H&E staining of SI and cecal tumors. Regions of invasion (black 
dashed box) are shown under higher magnification. Invasion into the submucosa and 
muscle wall (dark pink staining, arrows) can be seen.   
Cecal tumor Small intestine tumors A B 
SI tumor Cecal tumor 
4x 
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Pot1a, p53 intestinal tumors shows signs of genomic instability  
DNA was isolated from thirteen tumors grossly dissected from VCre, Pot1a, p53 
animals and assayed for genetic alterations through array comparative genomic hybridization 
(aCGH) analysis. The genotypes, tumor location and description are listed in Table 6. Tumor 
genomes were assayed against DNA pooled from the kidneys of five wild-type females using 
the Nimblegen Mouse 385K Whole Genome Tiling Arrays. Whole genome profiles were 
generated for each individual tumor (Figures 30 & 31). A few recurrent peaks and large areas 
of change are noted with asterisks. Tumors 3 and 6 appear to have the most regions of CNV 
with variations in large regions of several chromosomes.  
A more detailed analysis of genetic alterations was performed using Biodiscovery’s 
Nexus 5 software. The tumors used for array CGH were dissected from the GI tract at the 
time of necropsy, and though tumor margins were approximated using a dissection 
microscope, there is likely to be normal tissue in the samples. Attempts were also made to 
separate some of the muscle wall from the tumors, but H&E staining clearly shows that 
tumor cells invaded deep in to the muscle wall and the tumor tissue was mixed with many 
other cells types including stromal cells, lymphocytes, submucosal cells and even muscle 
wall (Figure 29C). The thresholds were set using the copy number losses of in the X 
chromosome of samples from males to determine the baseline setting. This occurred at 
approximately -0.2 on the log2 ratio scale. The thresholds were further lowered to -0.1 for a 
loss and 0.1 for a gain in an attempt to account for the non-tumor tissue DNA was mixed into 
the sample that was analyzed.  
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Table 6: Description of tumors used for aCGH experiments 
 
Sample Genotype Age (weeks) Location Tumor grade 
1 Pot1aint∆ p53F/+ 87 Small intestine  Low-grade adenoma 
2 Pot1aint∆ p53F/+ 87 Small intestine High-grade adenoma 
3 Pot1aint∆ p53F/F 78 Small intestine Invasive adenocarcinoma 
4 Pot1aint∆ p53F/F 63 Small intestine Invasive adenocarcinoma 
5 Pot1aint∆ p53F/F 63 Colon  High-grade adenoma 
6 Pot1aint∆ p53F/F 76 Small intestine Invasive adenocarcinoma 
7 Pot1aint∆ p53F/F 76 Small intestine Invasive adenocarcinoma 
8 Pot1aint∆ p53F/F 76 Cecum Invasive adenocarcinoma 
9 Pot1aint∆ p53F/F 76 Colon  Invasive adenocarcinoma 
10 Pot1aint∆ p53F/F 65 Cecum  Invasive adenocarcinoma 
11 Pot1aint∆ p53F/F 67 Cecum Invasive adenocarcinoma   
12 Pot1aint∆ p53F/F 83 Small intestine Invasive adenocarcinoma   
13 Pot1aint∆ p53F/F 83 Cecum  Invasive adenocarcinoma   
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Figure 30. Tumors from Pot1int∆ p53F/F mice show genomic alterations. Whole 
genome profiles for Tumors #1-7. The x-axis is divided by chromosomes and the 
results for each chromosome are color coded. The y-axis represents the copy number 
change on a log2 ratio scale, where the baseline (no change) is set to zero. A few 
recurrent peaks and large areas of change are noted with asterisks (*). 
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Figure 31. Tumors from Pot1int∆ p53F/F mice show genomic alterations. Whole 
genome profiles for Tumors #8-13. The x-axis is divided by chromosomes and the 
results for each chromosome are color coded. The y-axis represents the copy number 
change on a log2 ratio scale, where the baseline (no change) is set to zero. A few 
recurrent peaks and large areas of change are noted with asterisks (*). 
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Figure 32: Summary of aCGH results for thirteen intestinal tumors.  The top 
panel represents a summary of genetic alterations seen within the tumor set. The x-
axis is divided by chromosomes, from chromosome 1 on the far left, ascending to 
chromosome 19 on the right, ending with the X and Y chromosomes on the far right. 
The y-axis represents the percent recurrence of each alteration in the tumor set. Green 
bars represent copy number gains, while red bars represent copy losses. The bottom 
half of the figure displays the changes seen in each individual tumor. Each horizontal 
line represents an individual tumor and the variations in each sample can be seen. 
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Using these settings, the set of thirteen tumors were analyzed and a summary of the 
distribution of changes along the whole genome was generated (Figure 32). Of notes are 
several small regions of highly recurrent (present in >50% of tumors) gains and losses on 
chromosomes 4, 5, 8, 9, 13, 14 and 19(Figure 32, asterisks).  
The total number of regions with copy number variations was determined for each 
individual sample (Figure 33). The number of changes per sample ranged from 16 to 97 
regions, with a mean of 47.8 changes per tumor. Interestingly, the number of changes does 
not seem to correlate with tumor grade as an invasive cecal adenomcarcinoma (tumor #8) had 
as few as 27 changes, while a high grade adenoma with no invasion (tumor #2) had as many 
as 70 changes. There also seemed to be no correlation between age and copy number change: 
an invasive tumor from an 83-week old animal (#12) harbored only 34 regions of CNV, 
while a tumor from a 65-week old animal (#10) had 63 changes. This distribution suggests 
that each tumor harbors variable numbers of genetic alterations and serves as evidence that 
tumors generated by combined Pot1a and p53 deficiency are genomically unstable. The 
variation also suggested that the process is stochastic and telomere dysfunction with p53 
deficiency is permissive for the formation of random genome changes. 
 
DISCUSSION 
The results above describe the generation of a novel mouse model of intestinal tumorigenesis 
that is driven by telomere dysfunction. Our model of combined Pot1a and p53 deficiency 
proved to be permissive to cancer formation as aging Pot1aint∆ p53F/F mice developed tumors 
throughout gastrointestinal tract, including the small intestine, cecum and colon. These 
tumors were well-differentiated but showed frequent invasion into the submucosa, with some 
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Figure 33: Distribution of copy number changes. The total number of regions with 
copy number variations was determined for each sample and plotted above. The 
numeric value is listed above the bars. The number of changes per sample ranged from 
16 to 97 regions, with a mean of 47.8 changes per tumor.   
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 extending as deep as the muscle wall. These tumors resemble the GI tumors found in a small 
subset of late generation telomerase null mice with p53 haploinsufficiency(Artandi et al., 
2000). Similar to that model, our mice developed tumors with low multiplicity and a latency 
of 15 months. However, G5-G7 mTerc-/- p53+/- mice often succumb to other tumor types, 
such as lymphomas, breast and squamous cell, and a variety of sarcomas(Artandi et al., 
2000). Additionally, it requires five to seven round of intergenerational breeding to 
developed severely shortened telomeres. Our model is superior for studying telomere 
dysfunction in the GI tract because our phenotypes are limited to the intestines and we do not 
require intergenerational breeding to induce telomere dysfunction. 
Genomic profiling of the tumors revealed frequent copy number variation and 
heterogeneous profiles, also similar to tumors harvested from telomerase null p53 
heterozygous mice(O'Hagan et al., 2002), suggesting that telomere dysfunction was indeed 
driving genomic instability. These genomic alterations are currently being worked up to 
determine if there are any changes common to what is seen in human cancers and to 
determine if there are any new recurrent changes to explore. 
It is interesting to note that another group also tried to create a mouse model of 
telomere dysfunction in the setting of p53 deficiency in the intestine. This model paired 
conditional deletion of p53 in the intestines with late generation telomerase null mice(Begus-
Nahrmann et al., 2009). While they also concluded that p53 deficiency impairs the clearance 
of chromosomally unstable cells from intestines with severe telomere erosion, their model 
did not develop tumors. They postulated that although their model allowed them to bypass 
p53-dependent checkpoints, a second p53-independent checkpoint called crisis prevented 
tumor formation in their mice as progressive accumulation of cells with dysfunctional 
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telomeres lead to increased apoptosis(Begus-Nahrmann et al., 2009). The crisis checkpoint is 
thought to be bypassed in human cancers with the reactivation of telomerase(Maser and 
DePinho, 2002), a step that cannot occur in the telomerase null mice. Our model leaves 
telomerase activity intact, and may allow for bypass of crisis and possible progression to 
metastasis. 
 Some of the limitations of this model may provide directions that can be pursued in 
the future work towards improvement. The long latency of the tumor formation can possibly 
be decreased combining the conditional p53 knockout allele with a conventional p53 
knockout allele to form p53F/- mice. This would increase the probability of cells with 
homozygous deletion of p53 in the intestines because only one additional allele would need 
to be deleted conditionally, which may be helpful given the decreased X-gal staining and 
presumably decreased Villin-Cre activity in Pot1aint∆ mice. However, this system will only be 
beneficial if tumor latency is significantly shortened, as p53 haploinsufficiency throughout 
the organism also leads to lymphoma or sarcoma development. 
 Shortened tumor latency may also prevent the animals from succumbing to 
environmental contaminants. Many of our mice were euthanize without any symptoms of 
tumor formation. Unfortunately, there was an outbreak of fur mites in our mouse colony 
forcing us to euthanize the mice to relieve severe ulcerative dermatitis that was unresponsive 
to treatment. Given the invasive nature of the tumors seen on histology and the chromosomal 
instability seen on genomic profiling, we postulate that if the mice are allowed to live longer, 
we may be able to see more progression. 
 Another major limitation was the inability to monitor tumor formation. Our mutant 
mice developed tumors at a very low multiplicity, only one to four tumors per animal. While 
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this is an improvement over the APCmin models, which develops dozens of tumors but leads 
to early death due to the overwhelming load, low multiplicity means mice could bear the 
small tumor burden with few symptoms. In fact, tumor formation was quite insidious and 
most of the mice euthanized in this experiment were for symptoms not related to colon 
cancer formation. Some techniques that might be used for detection of tumor formation 
include in vivo imaging of mice. We attempted several protocols for computed tomography 
(CT) scanning and magnetic resonance imaging (MRI), however, the results were not robust 
enough to warrant the cost (data not shown). Because the tumors that develop in our Pot1aint∆ 
p53F/F mice were usually flat and thin, they were difficult to detect using these modalities. 
Furthermore, tumors often developed in the small intestines and the tortuous nature of this 
organ made it difficult to visualize on scans. We finally settled on using fecal occult blood 
testing (FOBT) to look for signs of occult GI bleeding due to tumor formation. The results 
from this test showed that positive results on this assay usually required tumors of at least 
4mm in size (data not shown). However, results could easily be false positive if the animals 
had cuts or sores on its skin that it may have groomed. Future developments in animal 
imaging, such as endoscopy, may provide a better method of monitoring tumor formation 
and possibly progression.   
 Another major limitation that prevented further analysis of the tumors was the lack of 
material to work with. Several factors contributed to this problem. First, the low multiplicity 
of tumor formation in this model limits the number tumors that can be harvested. Second, 
while some of the tumors stretched as long as 15mm at its longest dimension, most ranged 
between 2-4mm. Furthermore, most tumors fell in the category of flat lesions with raised 
edges, so that there was very little volume of tissue to work with. Finally, because this 
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morphology mimics irregular epithelium overlying lymphoid aggregates, half of the tumor 
was taken tissue sectioning to verify that it was indeed a tumor and determine it grade 
through H&E staining. Therefore, we used all of the material harvested from the thirteen 
tumors for aCGH was extracted for DNA.   
One technique that might help to expand the amount a material available from each 
tumor for future experiments is cell culture. Creating cell cultures from tumor tissue would 
solve several problems. First, there would be plenty of cells to harvest DNA, RNA and 
protein from to perform further validation experiment, especially cytogenetics. Cytogenetic 
techniques such as sprectral karyotyping (SKY), have been used previously in verifying 
genomic instability and picking up chromosomal translocation induced by telomere 
dysfunction(Artandi et al., 2000; Maser et al., 2007). Furthermore, general karyotyping of 
genomes could pick up details such as aneuploidy and whole chromosome gains and losses 
on a single cell level. Second, cell cultures would help enrich for the colon cancer cells, as 
the normal stromal cells surrounding should not grow. We attempted to make cell lines 
through several different protocols from intestinal tumors, using the APCmin mice for pilot 
studies because of the abundance of lesions in these mice. Unfortunately, we were unable to 
produce a culture of growing cells, and there were many incidents of contamination. 
Although a lot of antibiotics were used, it was difficult to completely wash away the large 
quantities of bacteria that normally inhabit the gut to obtain a sterile culture.  
  An alternative to cell culture to enrich for tumor cells is laser capture microdissection 
(LCM) of tumors from frozen sample. This method would also allow for the isolation of 
tumor cells, while limiting contamination from surrounding stromal cells. While this 
technique is used at MD Anderson, the aCGH platform we used for our experiments could 
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not support materials harvested in this fashion. Perhaps future experiments with different 
platforms will be able to take advantage of this technique. 
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THE EFFECT OF ATM ON POT1A-INDUCED TELOMERE DYSFUNCTION IN 
THE GI TRACT 
Animals with combined loss of Pot1a and ATR in the intestinal tract are not viable 
Pot1a contributes to the protection of telomeres by suppressing ATR-mediated DNA damage 
responses to the G-rich overhang(Denchi and de Lange, 2007; Guo et al., 2007). We sought 
to determine the affect of the ATR deficiency in our Pot1aint∆ mouse model by crossing it to a 
mouse harboring a conditional knockout allele of ATR (Brown and Baltimore, 2003). 
However, we were unable to generate mice with deletion of both genes (Table 7).  
This is not a surprising result as loss of ATR is very toxic to cells in culture as it leads to 
massive chromosomal fragmentation(Brown and Baltimore, 2003). Also, ATR deficient mice 
are not viable due to very early embryonic lethality(Brown and Baltimore, 2000). Previous 
experiments using a tamoxifen-inducible Cre system to conditionally knockout ATR in a 
grown mouse showed that deletion of ATR leads to transient but severe degenerative 
phenotypes in the intestines(Ruzankina et al., 2007). Therefore, it is not surprising that we 
were unable to generate many animals with chronic loss of ATR. Because ATR+/- mice 
occasionally developed tumors(Brown and Baltimore, 2000), we followed a small cohort of 
VCre+, Pot1aF/F, ATRF/+ mice for two years, but no tumor formation or intestinal 
abnormalities were detected (data not shown).  
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Table 7: Results of VCre+ Pot1aF/F ATRF/+ x VCre- Pot1aF/F ATRF/+ 
 
Genotypes  Expected  # Observed % observed 
VCre- Pot1a F/F ATR+/+ 1/8 (12.5%) 14 17.3% 
VCre- Pot1a F/F ATR F/+ 1/4 (25%) 22 27.2% 
VCre- Pot1a F/F ATR F/F 1/8 (12.5%) 12 14.8% 
VCre+ Pot1a F/F ATR +/+ 1/8 (12.5%) 15 18.5% 
VCre+ Pot1a F/F ATR F/+ 1/4 (25%) 25 30.9% 
VCre+ Pot1a F/F ATR F/F 1/8 (12.5%) *1 1.2% 
 Total: 89 mice  
* Mouse survived for 4 weeks. 
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ATM loss results in decreased overall survival 
While Pot1a mainly suppresses ATR-mediated DNA damage responses, deletion of 
Pot1a has been shown to also activate ATM(Wu et al., 2006). Furthermore, stable disruption 
of TPP1, whose main function is to facilitate Pot1a binding to telomeres, also leads to 
activation of the ATM pathway(Guo et al., 2007). It is postulated that while the immediate 
response to Pot1a loss is ATR-activation, ATM may also plays a role in a later response. 
Since in vivo deletion of Pot1a represents a chronic process, we sought to determine if loss of 
this checkpoint affected the phenotypes of our Pot1a mutants. To achieve this, we crossed 
our VCre, Pot1a mice with an ATM knockout mouse(Borghesani et al., 2000). This mouse 
was a straight knockout, so that ATM loss occurs throughout the entire organism. As seen in 
ATM-/- mice, these animals showed in shortened lifespan due to formation of thymic 
lymphoma (Figure 34), regardless of Pot1a status in the intestines. 
 
ATM deficiency rescues p21 activation and apoptosis  
A few mice were sacrificed at early timepoints (10 weeks) to examine the intestines for the 
microscopic characteristics seen in Pot1aint∆ crypts. Interestingly, in the setting of ATM 
deficiency, Pot1a loss does not manifest in increased apoptosis in the intestinal crypts 
(Pot1aint∆ ATM+/+: 0.60±0.12 vs. Pot1aint∆ ATM-/-: 0.17±0.08; t-test; p=0.05) (Figure 35A). 
Furthermore, examination of p21 IHC staining revealed that activation of p21 is also 
abrogated in Pot1a and ATM deficient intestines (Pot1aint∆ ATM+/+: 3.71±0.54 vs. Pot1aint∆ 
ATM-/-: 0.23±0.07; t-test; p<0.001) (Figure 35B&C). These results suggest that p53 
activation is not occurring in the absence of ATM. We postulate that loss of ATM may be  
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Figure 34: ATM deficiency leads to early death in Pot1a deficient mice. Kaplan-
Meier analysis showed that ATM deficiency lead to decreased overall survival, 
regardless of Pot1a status. 
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Figure 35: ATM deficiency rescues apoptosis and p21 activation in Pot1int∆ 
crypts.  (A) H&E staining of intestines harvested from various cohorts were examined 
for apoptosis. Quantification of apoptotic bodies per crypt demonstrated that ATM 
deficiency leads to decreased apoptosis in Pot1int∆ intestines as compared to 
Pot1int∆ ΑΤΜ+/+   (B) Representative p21 IHC staining in Pot1aint∆  ΑΤΜ+/+ and 
Pot1int∆ ΑΤΜ−/− intestines. p21 positive nuclei are indicated by the arrows. (C) 
Quantification of IHC staining shows a decrease in p21 activation in Pot1a deleted 
intestines when ATM is also deficient. 
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interfering with the DNA damage response to dysfunctional telomeres but recent attempts to 
assay for TIFs have been unsuccessful. 
 
Pot1aint∆ ATM+/- mice occasionally develop intestinal tumor formation in the aged mice 
While ATM-/- mice did not survive very long, we followed a cohort of 
Pot1aint∆ ΑΤΜ+/− mice for a period of two years. Routine euthanasia of these mice revealed 
occasional tumor formation in aged mice (Table 8). Of the sixteen mice older than 18 months 
that we examined, only four mice were observed to have tumors. These tumors were mostly 
well-differentiated adenomas, with one tumor showing signs of invasion. We postulated that 
loss of the wild-type ATM allele was necessary for tumor formation, but PCR experiments to 
verify this have been inconclusive. Taken together, these results suggest that loss of the ATM 
barrier may also be permissive to driving tumor formation in the setting of telomere 
dysfunction, possibly through the prevention of p53 activation in response to telomere 
dysfunction secondary to Pot1a loss.  
 
Discussion 
Pot1a binds specifically to the 3’ G-rich overhang of telomeres. It is has been shown 
contribute to the protection of telomeres from the DNA damage response by preventing the 
activation of an ATR-dependent DDR(Denchi and de Lange, 2007; Guo et al., 2007). We 
sought to determine the effect of losing this checkpoint in our in vivo model of Pot1a 
deficiency by generating a VCre+ Pot1aF/F ATRF/F mouse. However, we were unable to 
produce this mouse. This result is not surprising given that ATR is an essential gene for cell 
survival(Brown and Baltimore, 2003). Deletion of ATR from cells in culture lead to rapid 
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Table 8: Pot1aint∆ ATM+/- mice occasionally form tumors 
 
Age range Animals with 
tumors 
multiplicity Size range 
(diameter) 
12-15 months 0/4 n.a n.a. 
15-18 months 0/5 n.a. n.a. 
18-21 months 1/4 1 3mm 
21-24 months 3/12 1-2 3-8mm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-invasive Pot1aint∆ ATM+/- adenocarcinoma 
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chromosomal instability and cell death(Brown and Baltimore, 2003). Conditional deletion of 
the ATR in mice using an inducible Cre system resulted in massive cell death in highly 
proliferative compartments, especially in the intestinal tract(Ruzankina et al., 2007).  
Since we were unable to remove the ATR checkpoint, we decided to target ATM, 
which is also a potent transducer of the DNA damage response. In response to telomere 
dysfunction, ATM activation is typically associated with severe telomere erosion or loss of 
the TRF2 protein(Karlseder et al., 1999), both of which are thought to resemble double 
strand breaks. However, there is some evidence that ATM activation may play a role in the 
response to Pot1a loss. Western blots performed on cells that have lost Pot1a(Wu et al., 
2006) or stably express a TPP1-mutant that prevents Pot1a from binding to telomeres 
(TPP1∆RD)(Guo et al., 2007) show activation of ATM. Those results suggest that ATM-
mediated DDR may play a role in chronic loss of Pot1a. 
These results from this model suggest that ATM is necessary for activation of p53 in 
response to Pot1a loss, as Pot1aint∆ ATM-/- intestines fail to activate apoptosis and p21. These 
results are surprising because ATM deficiency does not affect the DDR to shortened 
telomeres in late generation telomerase null mice(Wong et al., 2003). This may suggest that 
ATM response to telomere uncapping due to Pot1a deletion triggers a different ATM 
response than critically short telomeres. 
A small subset of aging Pot1aint∆ ATM+/- produce tumors in the gastrointestinal tract, 
suggesting that abrogation of the ATM DNA damage checkpoint may also be a good model 
for telomere driven intestinal tumorigenesis. If this model is to be pursued further, I would 
recommend using a conditional ATM knockout allele to restrict ATM deletion to the 
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intestinal. This would bypass the early death caused by thymic lymphoma to allow the 
Pot1aint∆ ATM-/- GI phenotype time to manifest, possibly shortening tumor latency.  
 Finally, future work may combine Pot1a deletion with both p53 and ATM deficiency. 
Loss of both barriers to genomic stability may provide a model with shorter tumor latency 
and more chromosomal changes. Previous experiments have combined p53 and ATM 
deficiency with the telomerase knockout mouse to generate a model of lymphoma with 
unstable genomes (Maser et al., 2007). Work from this model has suggested that genetic 
changes seen in tumors with unstable genomes driven by telomere dysfunction, p53 and 
ATM deficiency, are similar to those seen in a variety of human tumors(Maser et al., 2007). 
These results suggest that genetic information found in tumors from these mouse models can 
be used as a filter for deciphering important genetic changes in human tumors. Perhaps future 
work with our Pot1a conditional model can yield such information to facilitate new gene 
discoveries based on telomere dysfunction in gastrointestinal tumors or other organ systems. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
The results of this manuscript describe the generation of a novel mouse model of 
intestinal tumorigenesis that is driven by telomere dysfunction. Taking advantage of the 
similar effects of telomere uncapping due to loss of the Pot1a telomere binding protein, we 
first created a mouse model of telomere dysfunction in the gastrointestinal tract that does not 
require multiple rounds of intergenerational matings necessary in the telomerase knockout 
models. First, we created a novel mouse model of telomere dysfunction in the gastrointestinal 
tract through the targeted deletion of the telomere binding protein, Pot1a. While our model 
does not show the overall morphological features of critical telomere shortening, such as 
blunting or atrophy of villi(Rudolph et al., 1999), the VCre, Pot1a mice developed various 
microscopic changes in the intestinal epithelium that are similar to late generation telomerase 
null animals with critically short telomeres (Choudhury et al., 2007; Rudolph et al., 1999). 
Pot1a deletion led to increased apoptotic cells in the crypts, as well as upregulation of p53 
and p21 expression. Finally, Pot1a deletion leads to increased cells with TIFs, an indicator of 
activation of the DDR in response to dysfunctional telomeres. These data correspond to 
previous work in cell culture, which has shown that deletion of Pot1a leads to a DNA 
damage response, which activates p53 to trigger cell cycle arrest through p21 or apoptosis 
(Wu et al., 2006), supporting the conclusion that in vivo consequences of Pot1a deficiency is 
similar to those seen in vitro.  
Our second mouse model featuring combined Pot1a and p53 deficiency proved to be 
permissive to cancer formation as aging Pot1aint∆ p53F/F mice developed tumors throughout 
gastrointestinal tract, including the small intestine, cecum and colon. These tumors were 
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well-differentiated but showed frequent invasion into the submucosa, with some extending as 
deep as the muscle wall. These tumors resemble the GI tumors found in a small subset of late 
generation telomerase null mice with p53 haploinsufficiency(Artandi et al., 2000). Similar to 
that model, our mice developed tumors with low multiplicity and a latency of 15 months. 
However, G5-G7 mTerc-/- p53+/- mice often succumb to other tumor types, such as 
lymphomas, breast and squamous cell, and a variety of sarcomas(Artandi et al., 2000). 
Additionally, it requires five to seven round of intergenerational breeding to developed 
severely shortened telomeres. Our model is superior for studying telomere dysfunction in the 
GI tract because our phenotypes are limited to the intestines and we do not require 
intergenerational breeding to induce telomere dysfunction. 
It is interesting to note that another group also tried to create a mouse model of 
telomere dysfunction in the setting of p53 deficiency in the intestine. This model paired 
conditional deletion of p53 in the intestines with late generation telomerase null mice(Begus-
Nahrmann et al., 2009). While they also concluded that p53 deficiency impairs the clearance 
of chromosomally unstable cells from intestines with severe telomere erosion, their model 
did not develop tumors. They postulated that although their model allowed them to bypass 
p53-dependent checkpoints, a second p53-independent checkpoint called crisis prevented 
tumor formation in their mice as progressive accumulation of cells with dysfunctional 
telomeres lead to increased apoptosis (Begus-Nahrmann et al., 2009). The crisis checkpoint 
is thought to be bypassed in human cancers with the reactivation of telomerase(Maser and 
DePinho, 2002), a step that cannot occur in the telomerase null mice. Our model leaves 
telomerase activity intact, and may allow for bypass of crisis and possible progression to 
metastasis. 
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 Our final mouse model paired loss of Pot1a with ATM deficiency. In response to 
telomere dysfunction, ATM activation is typically associated with severe telomere erosion or 
loss of the TRF2 protein(Karlseder et al., 1999), both of which are thought to resemble 
double strand breaks. However, there is some evidence that ATM activation may play a role 
in the response to Pot1a loss. Cell culture experiments with cells deficient in Pot1a(Wu et al., 
2006) or cells with mutant TPP1(Guo et al., 2007) can lead to ATM activation, suggesting 
that ATM-mediated DDR may play a role in chronic loss of Pot1a. The phenotypes seen in 
our VCre, Pot1a, ATM mouse models support this theory and further suggest that ATM is 
necessary for activation of p53 in response to telomere uncapping, as Pot1aint∆ ATM-/- 
intestines fail to activate apoptosis and p21. These results are surprising because ATM 
deficiency does not affect the DDR to shortened telomeres in late generation telomerase null 
mice(Wong et al., 2003). This may suggest that ATM response to telomere uncapping due to 
Pot1a deletion triggers a different ATM response than critically short telomeres. 
Furthermore, a small subset of aging Pot1aint∆ ATM+/- produce tumors in the gastrointestinal 
tract, suggesting that abrogation of the ATM DNA damage checkpoint may also be a good 
model for telomere driven intestinal tumorigenesis.  
 The phenotypes seen in the p53 and ATM colonies suggest that a combination of 
Pot1a loss with both p53 and ATM deficiency may possibly result in a model with even more 
pronounced phenotypes. Loss of both barriers to genomic stability may provide a model with 
shorter tumor latency and more chromosomal changes. Previous experiments have combined 
p53 and ATM deficiency with the telomerase knockout mouse to generate a model of 
lymphoma with unstable genomes (Maser et al., 2007). Work from this model has suggested 
that genetic changes seen in tumors with unstable genomes driven by telomere dysfunction, 
  - 91 - 
 
p53 and ATM deficiency, are similar to those seen in a variety of human tumors(Maser et al., 
2007). These results suggest that genetic information found in tumors from these mouse 
models can be used as a filter for deciphering important genetic changes in human tumors. 
Perhaps future work with our Pot1a conditional model can yield such information to facilitate 
new gene discoveries based on telomere dysfunction in gastrointestinal tumors or other organ 
systems. 
 Genomic profiling of the VCre, Pot1a, p53 tumors revealed frequent copy number 
variation and heterogeneous profiles, which is similar to tumors harvested from telomerase 
null p53 heterozygous mice(O'Hagan et al., 2002), suggesting that telomere dysfunction was 
indeed driving genomic instability. Genetic diversity and the wide variation of tumor 
genomes is one of the barriers to development of effective treatments for solid tumors, such 
as colorectal cancer. It is the reason why one patient treated with a particular drug can go into 
remission, while that same therapy will have no effect on another patient’s tumor. Future 
work with this model may also elucidate new gene mutations and genetic pathways to target 
with therapeutics. 
One major limitation of this model was the inability to monitor tumor formation. 
However, there are new techniques for in vivo imaging of mouse models that are currently 
being developed and used at other institutions. For instance, it is now possible to perform 
endoscopic imaging of mouse intestines using fiber optic technologies (Becker et al., 2005). 
If these techniques can be applied to our model, one could imagine even more questions that 
these mice can be use to answer. For instance, if endoscopic techniques for the mouse GI 
tract can be modified to take biopsies early and late during tumor develop, we could compare 
the genetic make-up or protein expression to look for targets involved in cancer progression. 
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This technique could also open up the possibility of using this mouse model for testing 
therapeutics. It would allow for monitoring of tumors for treatment effect as growth or 
regression could be monitored while sparing the animal from early euthanasia. Also, 
profiling pre-treatment biopsies may allow us to determine which genomic changes make a 
tumor more susceptible or more resistant to a particular type of treatment. For these 
applications, the variable genetic profiles of tumors from one animal to another more closely 
recapitulate the diversity of human tumors, making it a unique model for studying these 
phenomena.  
Advances in cancer genomics are fueling the push towards personalized medicine, the 
idea that treatment regimens can be individualized to each person’s tumor according to its 
genetic make-up. The unique nature of this mouse model of sporadic colon cancer driven by 
telomere dysfunction may provide a valuable tool for preclinical trials of therapeutics based 
on this concept. 
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 MATERIALS AND METHODS 
 
DNA extraction from tissue  
Tissue was harvested from animals at autopsy and rinsed immediately with ice cold 
phosphate buffered saline (PBS).  Intestinal samples were obtained by scraping epithelial 
cells with a scalpel. Tissue was digested using 450µl Cell Lysis Solution (Qiagen) and 
10µl Proteinase K (20mg/ml) at 55oC overnight. Samples were then treated with RNase A for 
30 min – 1 hour at 37oC. After addition of Protein Precipitation Solution (Qiagen), samples 
were spun for 30 minutes at 13,000 rpm. The DNA was precipitated from the supernatant 
with isopropanol and spun down. After washing with 70% ethanol, DNA pellets were air 
dried and the resuspended in 1X TE. Purity of samples was determined through Nanodrop 
and 1% agarose gels. If further purification was necessary, the samples were mixed with an 
equal volume of phenol-chloroform and spun down. The top aqueous layer was transferred to 
a new tube and the process was repeated. Then the top layer was transferred to a new tube, 
mixed with an equal volume of chloroform and spun down. DNA was precipitated with the 
top aqueous layer with 1/10 volume of 3M NaOAc, 3 times volume of 100% ethanol and 
incubated at -20oC for 2 hours. After spinning down, the pellet was air dried and then 
resuspended in 1xTE. 
 
Genotyping of animals and tissue 
Genotyping of animals was accomplished through PCR of tail or tissue DNA using primers 
and protocols previously described for each mouse line (Table 9). 
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Paraffin-embedding and H&E staining of tissue  
Tissues harvest from animals at autopsy was rinsed with ice cold PBS immediately. Non-
intestinal tissues were placed into cassettes and fixed in 10% formalin (Fisher) at room 
temperature for 24-48hrs. Cassettes were then transferred to 70% ethanol for storage before 
further processing. Intestines were dissected from the animal and washed in ice-cold PBS. 
They were further cleaning by flushing the lumen with ice cold PBS using a 10ml syringe 
and an 18g-feeding needle. The tissue was then fixed in 10% formalin for 24-48hrs at room 
temperature. The intestines were then cut open longitudinally and rolled with forceps. The 
Swiss rolls were pinned with a 26-gauge needle and stored in 1xPBS for 24-48hrs. The 
intestinal rolls were then sliced in half, placed in cassettes, and stored in 70% ethanol until 
further processing. The samples were then submitted to the MD Anderson Histology CORE, 
where the tissue were embedded in paraffin and cut into 5 micron section. Hematoxylin and 
eosin (H&E) staining was also performed at the Histology CORE according to standard 
protocols. 
 
TUNEL assay 
TUNEL assay was performed on paraffin embedded tissue using the Apoptag Kit (Millipore) 
according to the instructions. Briefly, paraffin-embedded tissue sections were run through a 
xylene to alcohol gradient and rinsed with 1x PBS. The sections were pretreated with a 
Proteinase K solution (20µg/ml) for 15 minutes at room temperature. After washing with 
ddH2O, the slides were then quenched with 3% H2O2 for 5 minutes at room temperature. 
Slides were rinsed with 1xPBS and then incubated briefly with Equilibration buffer. The 
slides were treated with TdT enzyme for one hour at 37oC. The reaction was stopped 
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STOP/wash buffer for 10 minutes at room temperature. Anti-digoxigenin solution was 
applied for 30 minutes at room temperature, followed by washes with 1x PBS. The DAB 
solution (Vector) was prepared with 2 drops, buffer, 4 drops reagent, 2 drops H2O2, and 2 
drops nickel in 5ml H2O, and applied to the specimen for 3-6 minutes. The slides were 
washed with water before counterstaining with Nuclear Fast Red (H-3403, Vector) for 45 
seconds to 1 minute, followed by more washing. The sections were through a reverse alcohol 
to xylene gradient and a glass coverslip was mounted with Permount. Analysis of TUNEL 
slides were performed on the Nikon 80i Upright Microscope using the NIS-Elements AR 3.1 
software.   
 
Immunohistochemical (IHC) staining 
IHC staining on paraffin embedded tissue sections was performed at the Histology and 
Tissue Processing Facility Core at MDACC Science Park – Research Division in Smithville, 
Texas. Tissue sections were stained for p53 and p21 according to their standardized 
protocols. Slides were analyzed through brightfield microscopy on a Nikon 80i Upright 
Microscope and pictures were taken using NIS-Elements AR 3.1 software. 
 
Immunofluorescence (IF) staining 
Sections of paraffin embedded tissue were run through a xylene to alcohol gradient and 
rinsed with ddH2O. Epitope retrieval was performed with Antigen Unmasking Solution 
(Vector) diluted 1:100 in ddH2O, steamed for 45 minutes, and cooled for 25 minutes. Slides 
were rinsed with ddH2O and then 1xPBS. Slides were blocked with 10% goat serum/PBS for 
30 minutes to 1 hour at room temperature. Sections were incubated with primary antibodies 
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diluted in 10% goat serum/PBS at 4oC overnight. For double staining, both primaries were 
added at the same time. The primary antibodies were diluted in the following manner: mouse 
monoclonal γ-H2AX (Millipore #05-636; 1:200), rabbit polyclonal γ-H2AX (Millipore #07-
164; 1:200), mTRF2 (1:200), BrdU (BD #347580; 1:100), beta-catenin (BD #610153; 
1:100), Cox-2 (Cayman #160162; 1:100). After washing with PBS, Alexa-conjugated 
fluorochromes (see below) were diluted 1:200 in 10% goat serum/PBS and incubated at room 
temperature for 1 hour. Slides were rinsed with PBS, and then samples for fluorescent 
microscope analysis were mounted with Vector Shield mounting media with DAPI. Samples 
for confocal analysis were counterstained with TO-PRO-3 (Invitrogen #T3605), diluted 
1:1000 at room temperature for 20 minutes. After another rinse with PBS, the coverslip was 
mounted on with Slowfade Gold (Invitrogen #S36936).  Fluorescence microscopy was 
performed on a Nikon Eclipse 80i microscope using MetaMorph software. Confocal imaging 
was performed on a Zeiss LSM 510 Confocal microscope. 
Secondary antibodies used included: Alexa Fluor 568 goat anti-rabbit (Molecular 
Probes #A11011), Alexa Fluor 568 goat anti-mouse (Molecular Probes #11004), Alexa Fluor 
488 goat anti-rabbit (Molecular Probes #A11070) and Alexa Fluor 488 goat anti-mouse 
(Molecular Probes #A11001). 
 
β-galactosidase activity assay 
Tissues were dissected from animals at the time of autopsy, washed with ice cold PBS, and 
fixed in 4% paraformaldehyde on ice for 20 minutes. Tissues were then embedded in OCT 
and flash frozen. 10 micron frozen tissue sections were cut in a cryostat and immediately 
fixed with 0.2% glutaraldehyde for 2 minutes and then immersed in X-gal staining solution 
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(1mg/ml X-gal, 5mM potassium ferricyanide, 5mM potassium ferrocyanide, 0.2% NP-40, 
0.1% sodium deoxycholate, 2mM MgCl2) overnight at 37oC. Slides were then washed in 
PBS before going through an alcohol to xylene gradient. Coverslip was mounted with 
Permount. Slides were analyzed through brightfield microscopy on a Nikon 80i Upright 
Microscope and pictures were taken using NIS-Elements AR 3.1 software. 
 
RT-PCR 
Tissue was harvested from animals at autopsy and flash frozen. RNA isolation was 
accomplished using Trizol as outlined by the product guide. Briefly, tissue was homogenized 
in 1ml Trizol and then incubated at room temperature for 5 min. 200µL of chloroform was 
added and the sample was incubated for an additional 3 minutes at room temperature. 
Centrifuge at 13,000 rpm for 15min at 4oC. The top aqueous layer was transferred to a new 
tube. 500µl of isopropanol was added and the sample was then incubated at room 
temperature for 5 min. Centrifuge 13,000 rpm for 10min at 4oC. Discard supernatant and 
wash with 70% ethanol. Spin down and air dry the pellet. Resuspend in RNase/DNase free 
water. 
RT-PCR was performed directly with RNA using the Taqman One Step RT-PCR 
Mastermix (Applied Biosystems/Roche). Pot1a was assayed using Taqman Custom Gene 
Expression Assay probes for exon 4. Results were normalized to GAPDH expression, which 
was determined with Taqman murine GADPH primers. All samples were run in triplicate. 
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Chemical induction of colon tumors (AOM-DSS model) 
10-15 week old VCre, Pot1a animals from each cohort were treated with a single injection of 
AOM (10mg/kg body weight). Immediately after the injection, the mice were fed a one week 
course of 3% DSS water, followed by two weeks of regular water. This was repeated two 
more times for a total of three cycles. Tumor evaluation was performed at 10 weeks or 15 
weeks after the AOM injection. 
 
Irradiation experiments 
Mice were dosed in the Mark I25 irradiator which has a 137Cs line source. The mice were first 
placed in a plastic CD contained with ventilation holes punched in. The time of exposure was 
calculated by the following equation: 
 Time =          desired dose (cGy)      - 0.005min 
                                0.98 x 315 cGy*min-1 
 
Array comparative genomic hybridization (aCGH) 
Array CGH was performed by the MD Anderson Genomics CORE on a Nimblegen 385K 
Whole genome tiling array (Roche). DNA was extracted from tumors as described above. 
Control DNA was pooled from the kidneys of five wild-type female mice. Raw data was 
processed with Imagene by the Core. Analysis was performed using the Nexus 5 software 
with the following settings: High gain = 0.5, gain = 0.1, loss = 0.1, big loss = -0.5. 
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Table 9: Genotyping primers and conditions 
Genotype Primer sequence Conditions 
Pot1a  
(WT/ floxed) 
EcoRI-21196:  5’-  CTC GAA TTC CAT CTC CTC  
                               CCA GTA CTC TCT CAG 
Confirm_20560:  5’-  GGA ACT GGT ACG TAT CAG TGT 
GTG TGG 
94oC    0:30 
60oC    0:30     
72oC    1:00    x 30 cycles 
Pot1a  
(delta)  
EcoRI_21196:  5’-  CTC GAA TTC CAT CTC CTC  
                                  CCA GTA CTC TCT CAG 
Delta:  5’-  ACA CGG ATC CTG AGC CAT AAA CAT              
 GCC ACA CAA AGG 
94oC    0:30 
60oC    0:30 
72oC    1:00    x 30 cycles 
P53  
(WT/ floxed) 
p53loxFWB     5'-   AAG GGG TAT GAG GGA CAA GG 
p53loxRVB      5'-   GAA GAC AGA AAA GGG GAG GG 
 
94oC    1:00 
60oC    1:00 
72oC    1:00    x 35 cycles 
P53  
(delta) 
p53-1F:   5’-  CAC AAA AAC AGG TTA AAC CCA G 
p53loxRVB      5'-   GAA GAC AGA AAA GGG GAG GG 
 
94oC    1:00 
60oC    1:00 
72oC    1:00    x 35 cycles 
P53  
(KO) 
P53X7:  5’-  TAT ACT CAG AGC CGG CCT 
P53X6-5:  5’-  ACA GCG TGG TGG TAC CTT AT 
neoP53:  5’-  TCC TCG TGC TTT ACG GTA TC 
94oC    1:00 
62oC    1:00 
72oC    1:00    x 30 cycles 
ATM CZ514:  5’- GTA GTA ACT ATT AGT TTC GTG CA  
CZ513:  5’- TAG GGT GTA CTA GTG GAG GA  
CZ054:  5’- GCT GGA CGT AAA CTC CTC TTC AGA C  
94oC    0:40 
55oC    0:40 
72oC    0:45    x 30 cycles 
Villin-Cre MVP+5498:  5’- ACA GGC ACT AAG GGA GCC AATG  
MVP+6378:  5’- GAT TCA GGT CAG AAA GAG GTC ACA 
G   
CreORF:       5’- CAT GTC CAT CAG GTT CTT GCG 
94oC    1:00 
59oC    1:00 
72oC    1:30    x 35 cycles 
APCmin IMR0033:  5’-  GCC ATC CCT TCA CGT TAG 
IMR0034:  5’-  TTC CAC TTT GGC ATA AGG C 
IMR0758:  5’-  TTC TGA GAA AGA CAG AAG TTA 
94oC    0:30 
55oC    1:00 
72oC    1:30    x 35 cycles 
Rosa26-LacZ 
(R26R) 
IMR0315:   5' -   GCG AAG AGT TTG TCC TCA ACC    
IMR0316:   5'-   GGA GCG GGA GAA ATG GAT ATG 
IMR0883:   5'-   AAA GTC GCT CTG AGT TGT TAT 
94oC    0:30 
65oC    0:45       
72oC    1:00    x 35 cycles 
ATR GATR-I#5:   5’-TAC ATT TTA GTC ATA GTT GCA TAA 
CAC 
GATR-I#15:  5’- CTT CTA ATC TTC CTC CAG AAT TGT 
AAA AGG 
 
Ramp 1.5oC/s to 94oC 
94oC    1:00 
Ramp 1.5oC/s to 62oC 
62oC    2:30 
Ramp 1.5oC/s to 72oC 
72oC    2:30    x 35 cycles 
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